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Abstract 
Background: Quality of Life (QoL) is a strong predictor of outcome for end stage renal 
disease patients. The Purpose of kidney transplantation is to improve the quality of life for 
patients with end-stage renal disease. It is the optimal treatment for those patients. The aim 
of this study was to measure QoL in renal transplant patients in Bethlehem and North 
Hebron in Palestine. 
Method: A descriptive, cross-sectional study was performed on 109 renal transplant 
patients referred to Ministry of Health- primary healthcare clinics of Bethlehem and north 
Hebron in Palestine from December 2016 to April 2017,by using Kidney Transplant 
Questionnaire (KTQ-25) for the assessment of QoL and determining the effect of socio-
demographic variables on QoL. The reliability of KTQ-25 was determined 0.74 by 
Chronbach's Alpha method. Data were analyzed by SPSS 17 and descriptive analytic 
statistics. 
Result: The mean quality of life for kidney transplant patients was(4.02±0.84). The highest 
score of the KTQ was the appearance dimension(5.40±1.23) while the lowest was related 
to the uncertainty/fear dimension (3.36±1.23).The sample of 109 kidney transplant 
recipients consisted of mostly males (79.8%),females( 20.2%),their mean age 
was(41±24) years. Most were married 81.7%,45.9% without work, 53.2%with low 
income,47.7% attributed ESRD to (other reasons), (66.1%) of kidney donor’s type were 
biologically blood related. Most common physical problems were aching and tired legs 
(68.8%). There was a significant effect of marital status on QoL, single patients had higher 
QoL than married ones (p = 0.034).No significant difference was observed (p>0.05) 
between other socio-demographic variables and the QOL scores. 
IV 
Conclusion: Quality of life for kidney transplant patients in our sample was moderate. 
Results of our study points to the need for support from the whole society, government, 
family, and medical staff, and the need to design plans for solving recipients problems and 
increasing their quality of life 
Key words: Quality Of Life, Renal Transplantation, Kidney Transplant Questionnaire 
(KTQ-25), Palestine. 
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Chapter 1: Introduction  
 
1.1 Kidney Transplantation 
Renal kidney transplantation (KT) is the surgical placement and vascular integration of a 
human kidney from a living or cadaveric donor into a patient who has end stage renal 
disease. 
Kidney transplantation is recognized as the treatment of choice among renal replacement 
therapies (RRTs) due to its proven bigger outcome on survival, morbidity and cost in 
comparison with other RRTs (Mcfarlane, Bayoumi, Pierratos, & Redelmeier, 2003; Wolfe 
et al., 1999). Patients who with kidney transplant experience a 68% lower risk of death 
compared with those waiting on dialysis for a transplant. This positive effect is afforded to 
all patients even the elderly and diabetics, who can gain more than ten years of extra life 
with kidney transplantation (Muehrer & Becker).  
 
As a point of fact, kidney transplantation is the most commonly performed organ transplant 
with high success rate and newer advancements have improved overall survival rates 
(Fiebiger, Mitterbauer, & Oberbauer, 2004). In addition, KT is proven to have a greater 
positive influence on health-related quality of life (HRQoL) in comparison with other 
RRTs(Cameron, Whiteside, Katz, & Devins, 2000; Gentile et al., 2008; Liem, Bosch, 
Arends, Heijenbrok‐Kal, & Hunink, 2007; Mcfarlane et al., 2003). When KT patients were 
compared with patients on dialysis, patients after KT show greater independence, higher 
engagement in social activities and an enhanced ability to work(Purnell et al., 2013). 
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1.1.2 Epidemiology of kidney transplantation 
According to the literature, there were 2,945 adult kidney transplants performed in the UK 
during 2015 and 2016, which shows a 5% increase compared to 2014-2015. The highest 
kidney transplant rates per 1000 dialysis patients in 2013 took place in Norway (N=210), 
Estonia (N=158), the Netherlands (N=146), Scotland (N=129), and the United Kingdom 
from 2000 to 2013, the prevalence of end stage renal disease (ESRD) patients living with a 
kidney transplant has continued to increase in every country with existing data and 
records("2015 USRDS Annual Data Report 
Volume 2: ESRD in the United States," 2015). In 2013 about 17,817 Canadians were 
living with a kidney transplant, in the same year, a total of 3,382 Canadians were waiting 
for a kidney transplant and 88 patients died waiting for one((CIHI), 2013). 
1.3 Kidney Transplantation in Palestine 
In Palestine, the average number of transplant patients is estimated to be at only 45–50 
cases per year(Younis et al., 2015), while the number of transplants performed until 2001 
from live donors was 420 transplant(Shahla, 2003). 
According to the Palestinian MOH about 255 kidney transplant procedure were performed 
successfully from 2010 till now without any cost from the patients.
 
The increasing incidence of end-stage kidney disease is clearly an important issue for 
health care professionals, as health and policy strategies are developed to decrease the 
burden of kidney failure and maximize HRQoL and psychosocial health through 
prevention strategies, early detection and better management of the disease.  
Palestinian Ministry of Health is the main health care provider for the kidney transplant 
patients management program. And the different treatment modalities of kidney transplant 
patients are free of charge. Kidney transplant  patients belong to group of Patients with 
―Special Diseases" and are eligible for a government health insurance. 
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1.4 Quality of Life 
The quality of life (QoL) is defined as the degree to which the experience of an individual's 
life meets that individual's wants and needs(Kerce, 1992).  QoL may be classified within 
five dimensions: physical well-being, material well-being, social well-being, emotional 
well-being, development and activity(Felce & Perry, 1995). Quality of- life measures 
changes in these five dimensions in order to evaluate the human and financial costs and 
benefits of new programs and interventions (Testa & Simonson, 1996). The World Health 
Organization (WHO) describes QoL as an individual's perception of their position in life in 
the framework of the culture and value systems in which they live, and in relation to their 
goals, prospects, standards, and worries(Organization, 1996). 
1.5 Health -related Quality of life 
When QoL is considered in the context of health and disease, it is commonly referred to as 
health-related quality of life (HRQoL) to distinguish it from other aspects of quality of life 
measurements("Health-Related Quality of Life and Well-Being," 2010). HRQoL has 
become very important health indicator for treatment policies which measuring the impact 
of the condition in patients and their diseases (Ferrans, Zerwic, Wilbur, & Larson, 2005). 
by describing physical, mental, social and behavioral components of well-being a as 
perceived by patients  (Bakas et al., 2012). 
Development and utilization of HRQoL instruments increased during the last decade with 
efforts to enhance both patient health and the value of healthcare services(Janodia, 2016). 
Health-related quality of life (HRQoL) was recognized as a model to include the patients’ 
perception in clinical practice(Abbott et al., 2011). HRQoL contains several attributes of 
health-related matters from the patients' viewpoint including physical, psychological, and 
social functioning and overall well-being. Many clinical studies have recognized the 
significance of HRQoL in various diseases, and it is progressively common to evaluate 
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disease-specific and generic HRQoL in clinical trials as a measure of patients' subjective 
state of health(Rostami, Tavallaii, Jahani, & Einollahi, 2011).  
Many studies concluded that HRQoL information is very important because it significantly 
improves the process of making clinical decisions, it improves the determination of the 
effectiveness of medical intervention, assesses the quality of care, measures the healthcare 
need of the general population and it helps better identify the causes and consequences of 
the differences in health(Rebollo et al., 2003). 
1.6 Role of pharmacists in QoL 
Pharmacists are members of the health care team and a direct patient care providers. They 
play a vital role in patient monitoring to determine side effects of medication specially in 
transplantation, they are very important  members of the transplant patient care team 
(Wiegel & Olyaei, 2016). Many studies approved that pharmacist interventions and other 
clinical pharmacy services for renal transplant and dialysis patients led to  improvement in 
all  health outcomes and QoL (Jacob, Joyal, & Sambathkumar, 2016). A study reported 
that pharmacist  counseling with regular intervals has give  significant improvement in the 
QoL of hemodialysis patients with that of control group (Shareef, Kripa, & Baikunje, 
2015). Another study which was determining the effect of pharmaceutical care on HRQOL 
in HD patients had result that patients who had pharmaceutical clinical care did not have 
lower HRQOL after 1 year and could have the same HRQOL for another year (Pai, Boyd, 
Chavez, & Manley, 2009). The presence of a clinical pharmacist in nephrology unit may 
improve pharmacotherapy and reduce medication complications and give a better QoL in 
these patients (Zolezzi, 2002)So studies recommended that every hospital must have 
clinical pharmacists in nephrology department to improve QoL . 
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1.7 QoL tools  
Interest in QoL measurement in clinical practices in order to ensure that treatment and 
evaluation are focused on the patient rather than the disease has only been noticeable in 
recent years(Higginson & Carr, 2001). 
 QoL tools can be grouped into two categories: generic and disease-specific scores. 
A disease-specific score is a more sensitive instrument because it emphasizes the clinical 
condition. To name a few: European quality of life-5 dimensions (EQ-5D), time trade off 
(TTO), standard gamble, health utility index (HUI), Finnish 15 dimensions (15D), Medical 
Outcomes Study 36-Item Short-Form Health Survey (SF-36), kidney disease quality of life 
(KDQoL), Karnofsky, sickness impact profile (SIP), general health questionnaire (GHQ), 
and World Health Organization quality of life (WHO-QoL) (Tonelli et al., 2011).  
Among the most popular global tools is the SF-36, while the Kidney Transplant 
Questionnaire (KTQ) is the most common as a disease-specific tool(Fiebiger et al., 2004)  
Kidney Transplant Questionnaire (KTQ) is a quality-of-life instrument designed 
specifically for kidney transplant recipients, it's a disease-specific questionnaire consisting 
of 25-items that is divided into five domains: physical symptoms (six items), fatigue (five 
items), uncertainty/fear (four items), appearance (four items), and emotional (six items) 
(Table1). A mean score ranging from 1 to 7 is reported for each of the five domains. 
To calculate the score of each dimension the sum of all the items in the dimension is 
determined and then divided by the number of items in that dimension, with higher scores 
representing better functioning, or fewer problems(Laupacis et al., 1993; Rostami et al., 
2011).  
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Table 1: Kidney Transplant Questionnaire (KTQ) instrument dimensions. 
No. Dimensions Items 
I.  Physical  Symptoms 
 
Six patient-specific items 
II.  Fatigue 
 
weak 
low level of energy 
sluggish 
increased tiredness 
very little strength 
III.  Uncertainty/Fear 
 
protective of transplant  
fear or panic related to rejection 
uncertain about the future 
worried 
IV.  Appearance 
 
excessive hair growth  
excessive appetite 
excessive weight  
acne 
V.  Emotional 
 
Irritable,difficult to get along with 
depressed 
anxious 
frustrated 
stubborn 
impatient 
 
The Short-form survey (SF-36) 
 is a survey that has been used in many studies to measure quality-of- life and it consists of 
eight dimensions, producing a profile of health-related quality of life. These dimensions 
are: 1) Physical Functioning; 2) Role Limitations due to Physical Functioning; 3) Bodily 
Pain; 4) General Health Perceptions; 5) Vitality; 6) Social Functioning; 7) Role Limitations 
due to Emotional Functioning; and 8) Mental Health. Raw scores are transformed into a 
score between zero and hundred for each dimension. Higher scores signify better health 
(Ware Jr & Sherbourne, 1992). Although SF-36 may be useful, it is not disease specific 
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1.8 Problem statement 
The WHO reports that lifestyle-related diseases and kidney disorders are in the top twenty 
leading causes of deaths in 2004 (Bauman, Phongsavan, Schoeppe, & Owen, 2006). 
Additionally, patients with end-stage kidney disease often experience complications which 
include cardiovascular disease, diabetes, hypertension, and other infectious complications 
(Sarnak et al., 2003).  
The purpose of kidney transplantation is to improve the quality of life for patients with 
end-stage renal disease (ESRD). It is the optimal treatment for those patients. 
Unfortunately, many patients may develop vascular problems, graft rejection, viral 
infections, obstructive hydronephrosis or lymphatic problems. This is reflected in the 
unsatisfactory scores of quality of life especially in patients experiencing acute graft 
rejection or adverse events resulting from immunosuppressive therapy (McIntyre, Stewart, 
& Clinical, 2009).  
1.10 Immunosuppressive therapy 
Choosing more powerful immunosuppressive drugs has resulted in better quality of life for 
patients by increasing graft survival, results in improvement in the cardiovascular 
complications and reduces the side-effects (Artz et al., 2004). 
Cardiovascular disease, infections, and malignancy, is the most leading causes of death in 
kidney transplant recipients with good functional kidney (Briggs, 2001). 
 
Adherence to immunosuppressive therapy is necessary to prevent graft rejection which 
result a higher number of hospitalizations and costs of therapy (Denhaerynck et al., 2009). 
Adherence and devotion to immunosuppressive therapy mostly affected by socio-economic 
and cultural factors such as age, gender, education, occupational situation, patient-related 
factors (forgetfulness, daily routines), condition-related factors (time since transplant, 
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depression), and therapy-related factors (Gonçalves, Reveles, Martins, Rodrigues, & 
Rodrigues, 2016). 
There is an evident need for a collaboration and partnership among the transplant center, 
community nephrologists, and primary care physicians who are involved in the long-term 
care of these patients to enhance QoL(Djamali et al., 2006).  
Kidney transplants is experienced differently by each recipient depending on the socio-
demographic, clinical and psychological factors(Vasudevan, 2014). The differences in the 
healthcare environments between countries could also affect the quality of life of the 
kidney transplant recipients(Niu et al., 2015). 
Fear of organ rejection and uncertainty about future health are great concerns for the 
kidney transplant patient. Those patients who had bad memories regarding the period of 
dialysis expressed greater fear of losing the graft and having to go back to the hemodialysis 
machine and all the associated complications(de Brito, de Paula, dos Santos Grincenkov, 
Lucchetti, & Sanders-Pinheiro, 2015). 
Additionally, kidney transplant recipients require careful follow-up in both the early (<6 
months) and late post-transplant period. Monitoring should concentrate on graft function 
and the most common complications of immuno-suppression therapy(Andany & Kasiske, 
2002). The long term success of a kidney transplant depends on several factors, all of them 
relate to the patient following recommended treatments required after the transplant. These 
include: healthy lifestyle, healthy diet, exercise, lab tests and clinic visits and 
immunosuppressant medication which must be taken in right dose and time by kidney 
transplant patients for their whole life . 
Therefore, understanding patients’ QoL has significant inferences for treatment and 
therapy decisions. 
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In Palestine, more than one study characterized quality of life of end-stage kidney disease 
patients undergoing dialysis. All studies suggested that there is a need to find other renal 
replacement therapies such as transplantation because of the low quality of life for patients 
undergoing dialysis in Palestine (A.Al-Shareef, 2011). There is no current data on the 
quality of life for kidney transplant patients in Palestine. 
 
1.11 Study Objectives: 
1. To measure QoL among renal transplant patients who visit MOH facilities in 
Bethlehem and North Hebron. 
 
2. To identify the effect of socio-demographic variables on the QoL of these 
patients. 
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Chapter 2: Literature review 
 
1.2 QoL and Kidney Transplantation 
Recent studies have shown that HRQoL improved after successful kidney transplantation 
in comparison to dialysis. These studies documented that renal transplantation is not only 
cheaper than renal replacement therapy on the long term and associated with less mortality 
rates, but also provides a better quality of patients' life. A successful kidney transplant 
confers a strong lasting protection from cardiovascular death, probably by reversing 
cardiovascular disease progression in ESRD patients (Meier‐Kriesche, Schold, Srinivas, 
Reed, & Kaplan, 2004). 
 
Prevention and early management of disease progression, cardiovascular complications, 
infections, and malignancies constitute the cornerstone of this collaborative effort to extend 
life span and allograft function(Fiebiger et al., 2004). 
A study by Zyoud et al. (2016) was performed from June 2014 to January 2015, to 
evaluate QoL of ESRD patients undergoing HD in all dialysis centers in the West Bank in 
Palestine. This study concluded that healthcare providers should be informed about the low 
HRQoL among patients with no formal education, female patients, whether the patient 
lives in refugee camps, and whether the patient has multiple co-morbid diseases and/or 
multiple chronic medications, and elderly patients in order to take measures to improve 
their quality of life(Sa’ed et al., 2016). 
Another study done by two Nursing students, Sayej and Qtait (2016), at Al-Quds 
University, Palestine measured quality of life of Palestinian renal failure patients under 
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hemodialysis which was moderate, they state that the moderate QoL can be made better by 
promoting health policies that enhance the level of satisfaction of renal failure patients and 
that stimulates staff awareness and training with regards to supporting and teaching about 
diet, medication and self-care and increase the attention on emotional, cognitive and social 
aspects of health. In addition to also focusing more about dialysis departments’ 
environment and facilities(S Sayej, 2016). 
One important Palestinian study done by Younis et al. (2015) provides a cost analysis on 
kidney replacement therapy options. The authors found that peritoneal dialysis (PD) and 
home hemodialysis (HD) are not widely available in Palestine due to the lack of skilled 
staff, specialists, and centers to follow those patients, provide training and home visits, and 
provide instructive programs for patients. All of these factors evidently show the 
advantages of transplantation. However, kidney transplants in Palestine are dependent on 
related, live donors rather than cadaveric donors, which consequently indicate that fewer 
patients are eligible for transplant. The authors further suggested that investing in sufficient 
competent staff, equipment, and clinical infrastructure to replace HD services with 
transplantation whenever there is available medical indication and suitable kidney donors. 
Their findings provide a better understanding of the expenses of kidney disease and help 
advise the Ministry of Health and other related parties in their development of short- and 
long-term strategies with the aim of saving costs and enhancing the quality of life(Younis 
et al., 2015).  
The extensive interaction between patients and health professionals is regarded as an 
important contributing factor to QoL, and needs more attention in the field of kidney 
transplantation. 
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A Master’s degree thesis defense held in 2011 at An-Najah National University identified 
the major risk factors of ESRD that lead to the onset of ESRD in the Northern West Bank, 
which recommends the need for conducting and improving national kidney transplantation 
programs in Palestine, and for raising community awareness about kidney donors(Basheer, 
2011). All these studies encourage the Ministry of Health in Palestine to draw attention to 
the field of kidney transplantation.   
Internationally, there are many studies that have been conducted to characterize HRQoL in 
kidney transplant patients worldwide. To start with, in 2009, a study was conducted in 
Tehran to measure QoL in renal transplant patients. It was performed on 220 renal 
transplant patients who were referred to transplantation and nephrology clinic of two 
Tehran city-selected hospitals. Kidney Transplant Questionnaire (KTQ-25) was used to 
collect the data. The highest score in this study was that of the dimension of body 
appearance and the lowest score in this study was the fear dimension. There was no 
statistical, significant difference in this study between the quality of life scores and the 
cadaveric transplant and live donors. The average quality of life was significantly higher in 
men. The authors discovered that Tehran city kidney transplant patients’ QoL level was 
moderate(Tayebi et al., 2010). 
Another study, conducted in China between July 2014 and December 2014, in which 136 
living donor kidney transplantation recipients were included and the Chinese version of 
KTQ was used. The highest score of the KTQ was found in the appearance dimension, 
while the lowest score was found in the uncertainty/fear dimension. The score for 
―Uncertainty/Fear‖ was the lowest among all dimensions of this study, which was unlike 
other findings. This variance could be caused by the differences in the selection of the 
subjects. For example, most of the other studies did not describe the source of the kidney, 
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and suggested that the recipients had feelings of fear and anxiety about the donors(Niu et 
al., 2015).  
Another similar study conducted in the USA in 2011 included 114 renal transplant 
recipients, who were post-transplant for more than two years, and who received 
immunosuppressant therapy. The KTQ was used to evaluate HRQoL in this study. In 
general, renal transplant recipients who are at least two years post-transplant are more 
clinically stable compared with other studies which consider renal transplant recipients 
within the first year of post-transplant. This consequently gives this study a more stable 
assessment of HRQoL KTQ-physical, KTQ-fatigue, KTQ-uncertainty/fear, and KTQ-
emotional subscales, ranging from 15% to 27% of respondents receiving the highest 
possible score. A substantial ceiling effect was present for the KTQ-appearance subscale, 
with 84% of renal transplant recipients receiving the highest possible score(Chisholm-
Burns, Erickson, Spivey, Gruessner, & Kaplan, 2011).  
Balaska et al. (2006) compared and evaluated health-related quality of life (HRQoL) in 
Greek adult transplant recipients before, and one year after successful renal transplantation 
(RT). They examined which parameters had the greatest effect on their HRQoL. The SF-36 
survey score was used in 85 Greek hemodialysis patients who underwent RT at the 
Transplant Unit of General Hospital of Athens of whom 44 were men and 41 were women. 
Thirty-nine patients in this study had received a kidney from a live, relative donor, and 46 
patients had received a kidney from a cadaver. The scale scores of a Greek version of the 
SF-36 survey were compared between the transplant and the hemodialysis patients. The 
authors also examined the relationship of the scale scores with the age of patients and the 
donor type. The overall HRQoL of renal allograft recipients was significantly better than 
that of hemodialysis patients. General health perception, role-physical functioning, role-
emotional functioning, and vitality were demonstrated to have a great positive effect on 
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patients’ HRQoL after RT. The lower the patient’s age at the time of transplantation, the 
higher the SF-36 scale scores. The type of the graft donor was also an important factor 
affecting HRQoL in RT patients(Balaska et al., 2006). 
A UK study was conducted to examine the quality of life (QoL) of the live donor renal 
transplant recipients pre- and post-transplantation, and correlate that with their pre-
transplant dialysis status and immunosuppressive regimens post-transplantation. In this 
study, 57 live donor renal transplant recipients and 38 healthy individuals as controls 
participated in Division of Renal Transplantation, Sheffield Kidney Institute. The Kidney 
Transplant Questionnaire (KTQ) and the Medical Outcome Survey Short Form 36 (SF-36) 
questionnaire were used to assess QoL.  
The post-transplantation scores in all SF-36 dimensions were significantly higher in the 
live donor renal transplant recipients, but remained lower than that of the control group. 
However, in the KTQ, all dimensions except appearance significantly increased post-
transplantation patients transplanted proactively and those on tacrolimus-based immuno-
suppressive drugs had significantly better QoL. All the patients who reported complaints 
pre-transplantation had a clinically and statistically significant improvement in QoL post-
transplantation(Shrestha, Basarab-Horwath, McKane, Shrestha, & Raftery, 2010). 
Bittencourt et al. (2004) in Brazil performed a 132 subject study in patients who underwent 
renal transplant at a university hospital between 1984 and 2001. The purpose of the study 
was to contrast the quality of life in renal transplant patients with functioning, operative 
graft and those who restarted dialysis after graft loss. The instrument used to assess quality 
of life was the WHO-QoL-Brief questionnaire.  
This study displayed a better quality of life in renal transplant patients with a functioning 
graft particularly with regards to the physical and psychological domains(Bittencourt, 
Alves Filho, Mazzali, & Santos, 2004). 
15 
 
 
On the same footsteps, at the Brazilian University Medical Center, a qualitative study was 
undertaken with kidney transplant recipients between August and December 2010, with the 
participation of 50 patients. In this study, a semi-structured interview was used as the 
method of data collection. The interview is made up of open-ended and closed questions, 
and is divided in two sections. The first refers to the patients’ clinical and socio-
demographic data, and the second inquiries about the main positive changes following KT 
and the principal difficulties patients faced following KT. 
The authors found that kidney transplantation caused various positive changes in the 
patient’s routine, with the return to daily life activities being the most important gain in the 
participants’ opinion. In relation to the stressors, fear related to loss of the graft, and 
questions relating to the immunosuppressive medication were the main challenges faced 
following transplantation(de Brito et al., 2015).
 
 
A research study held for a three-year period (between May 2010 and May 2013) by 
Mendonça et al. (2014) whose aim was to identify changes on the quality of life after the 
efficiency of kidney transplantation and to verify the influence of socio-demographic 
factors on the quality of life of a population that consisted of chronic renal failure patients 
receiving outpatient treatment at a referral center for kidney transplant in northeastern of 
Brazil. The inclusion criteria included a total of 63 patients aged over 18 years. Data was 
collected at a private location, using the WHO Quality of Life WHO-QoL- brief, in two 
steps in order to assess the perception of kidney recipients before and after transplantation: 
 In the first step transplant candidates on the waiting list were interviewed, 
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 In the second stage, candidates were interviewed after kidney transplantation, 
respecting the minimum interval of three months that was the necessary time for 
patient recovery and return to their daily life activities. 
The comparison between the mean scores of QoL domains before and after the transplant 
showed significant improvement in general QoL and in all evaluated domains as well as an 
affirmative influence of renal transplantation on the patients’ perception. This 
improvement was more significant in general QoL, physical health domain and social 
relationships domain. Socio-demographic factors did not have an effect on patients 
indicating that transplantation was the main factor that explains changes in quality of 
life(Mendonça, Torres, Salvetti, Alchieri, & Costa, 2014). 
 
In the years 2009 and 2010, about 90 kidney transplant patients were selected from 4 
hospitals in Tehran and were randomly assigned to 2 groups. The aim of this study was to 
compare the effect of the continuous care model with routine care on the quality of life 
among patients who received a kidney transplant. The continuous care model, proposed by 
Ahmadi (2001) as a native nursing care model, is used to establish and maintain a 
dynamic, interactive, and mutual relationship between the nurse, the patient, and the 
patient’s family, so that the QoL of the patients may be improved. In the experimental 
group, continuous care model was applied for 3 months and the control group received 
routine care.  
The scale scores of the Kidney Transplant Questionnaire concerning quality of life were 
compared between the two groups on a monthly basis. The quality of life scores increased 
in both groups, the mean scores of the experimental group were significantly higher than 
those in the control group at 1, 2, and 3 months(Raiesifar et al., 2014). 
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Georgieva et al. (2012) conducted a study on health related quality of life (QoL) and 
pharmacotherapy cost at the biggest Sofia Hospital serving all transplant patients in 
Bulgaria. The objective of the study was to analyze the cost of pharmacotherapy and the 
quality of life of patients after kidney transplantation in comparison to those with chronic 
kidney disease. The multidimensional questionnaire SF-36 was used to evaluate health 
related quality of life (QoL). Patients with chronic kidney disease had lower QoL in all 
domains when compared to transplanted patients. QoL in patients with kidney 
transplantation especially ensuing successful transplantations assures a normal life; the 
location in which individuals live and the general health state had a positive correlation. 
Moreover, people living in towns were shown to have better quality of life, probably due to 
the fact that they are closer to healthcare services. The findings of this study confirmed the 
fact that the chronic kidney disease severely hinders the quality of life. In addition, the 
study revealed that access to healthcare and higher spending on pharmaceuticals has a 
positive influence on the QoL of transplant patients(Georgieva et al., 2012). 
 
A regional study conducted at center Giza outpatient clinics for kidney Cairo University, 
Giza, from June 2013 till January 2014, actively followed approximately 500 recipients of 
a kidney transplant. A sample of 50 patients undergoing kidney transplantation was 
included in the study using the Short Form Health Survey (SF-36). 
Patients' education program enhanced patients HRQoL, their knowledge, their self-
efficacy, and their coping strategies. All dimensions of HRQoL of the patients were better 
after the education program when compared with that of prior to the intervention(Mersal & 
Aly, 2014). 
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An East Asian study conducted in the Republic of Korea (KNOW-KT) enrolled 1,000 KT 
recipients between 2012 and 2015 and followed them up to 9 years. The research is a 
multi-center, observational cohort study involving 8 transplant centers. The outcome in 
patients with kidney transplantation from 175 patients was analyzed. At the time of KT and 
at pre-specified intervals, clinical information, laboratory test results, functional imaging 
studies on cardiovascular disease and metabolic complications were recorded. The 
KNOW-KT intended to study allograft survival rate, cardiovascular events, and metabolic 
profiles as well as revealing the risk factors in Korean KT patients. The HRQoL of patients 
in the KNOW-KT study was assessed before transplantation and 2 years after 
transplantation using the Kidney Disease Quality of Life Short Form (KDQoL-SF) 
including chronic kidney disease targeted area and the Medical Outcome Study 36-item 
Short Form Health Survey (SF-36). All QoL scores including the total QoL score, chronic 
kidney disease targeted score, and SF-36 at the 2-year follow-up were significantly 
increased compared to baseline values. Both physical and mental scale scores were 
improved after transplantation(Lim et al., 2016). 
Another multi-center study took place in France between March 2007 and March 2008, 
which aimed to identify factors associated with health-related quality of life (HRQoL) 
through a comprehensive analysis of socio-demographic and clinical variables among renal 
transplant recipients. Data included socio-demographic parameters, health status, and 
treatment characteristics. To evaluate HRQoL, the Short Form-36 Health Survey (SF-36) 
and a HRQoL instrument for RTR were administered. 
In this study low SF-36 scores were in: older age, females, un-employed, lower education, 
and living alone individuals, high BMI, diabetes, infectious disease, critical illness and 
hospitalization in the last 4 weeks, non-compliance, former smokers, a long duration of 
dialysis, side effects related to general health and mental health or body modification. As a 
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result, the variables that predicted worse HRQoL in this study were: side effects, infectious 
disease, recent hospitalization and female gender(Gentile et al., 2013). Patients without 
employment or living alone were seen to have lower QoL scores, and women were seen to 
have lower QoL scores than men(Gentile et al., 2008). 
 
At Louis Pasteur University Hospital Transplantation centre in Kosice, Slovakia a study 
explored the association between post-transplant factors (kidney function, perceived side 
effects of immunosuppressive treatment, co morbidity, physical and mental health-related 
quality of life (HRQoL)) and social participation. The study included 331 patients who 
underwent a kidney transplant between the years 2003 to 2009. The evaluation was done at 
3 months to 6 years after kidney transplantation and their impact on graft loss and 
mortality for up to 10 years (follow-up). The Short Form Health Survey-36 and the 
Participation Scale were used, and information on all-cause graft-loss and mortality was 
noted. 
The researchers found that restrictions in social participation were associated with living 
alone, worse kidney function, more severe side effects of immunosuppressive treatment, 
and lower physical HRQoL. Additionally, social participation had a positive effect on 
long-term patient outcomes, decreasing the odds of graft loss and mortality over 10 years 
(Prihodova et al., 2015). 
A further study by Prihodova et al. (2010) focused on the role of personality and actual 
psychological distress in predicting HRQoL after KT. Socio-demographic parameters 
(gender, age, education, and average income), medical parameters (glomerular filtration, 
serum albumin, number of co-morbid diseases) and psychological parameter data 
(neuroticism, extroversion, and psychological distress) were collected from 177 kidney 
transplant recipients, and physical and mental HRQoL were measured using the SF-36.   
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Higher physical HRQoL was linked with younger age, higher education, and higher 
income, a low number of co-morbid diseases as well as lower neuroticism and distress 
levels. Higher mental HRQoL was associated with higher education and higher income 
alike; longer time from KT, higher extroversion and lower neuroticism and distress. Actual 
distress was the best predictor in both physical and mental HRQoL. Results of this study 
validate the importance of psychological distress in patients and its effect on their HRQoL 
after KT. It therefore can be useful in intervention programs focused on increasing 
HRQoL(Prihodova et al., 2010). 
A Middle Eastern study by Al-katheri et al. (2015) which explores and compares QoL in 
renal and liver transplant patients was conducted between January 2013 and January 2014 
in Saudi Arabia. A total of 151 renal transplant recipients sand 154 liver transplant 
recipients agreed to participate in the study. The WHOQoL instrument (WHOQoL-BREF) 
was used to evaluate QoL. 
The results show that renal and liver transplant recipients who were males, or single or 
married or had higher education or who were employed had higher QoL domain scores. It 
is worthy to note that less than 20% of patients were classified in the poor QoL category 
for each domain. The findings of this study indicated that both renal and liver transplant 
recipients had very high QoL domain scores in comparison with international data. 
Moreover, they were extremely satisfied with their QoL facets as indicated by the WHO-
QoL-BREF. Lower QoL results was notably linked with social disadvantage, which 
indicates that such patients may need more focused attention and counseling following 
transplantation(Alkatheri et al., 2015). 
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Chapter 3: Method 
 
1.3 Questionnaire and Translation  
The data collection tool used consisted of two parts: 
 Appendix 1: socio-demographic characteristics included  age, gender, marital 
status, employment status, educational level ,financial income and clinical variables 
include cause of ESRD disease, duration of previous replacement therapy 
(dialysis), type of donor and the time period since transplantation, and smoking 
status. 
 Appendix 2: Kidney Transplant Questionnaire (KTQ) for measuring the quality of 
life for kidney transplant patients.  
Advantage of Kidney Transplant Questionnaire KTQ: we use this questionnaire because of 
its advantage upon others, this disease-specific measures improve the sensitivity of QoL 
measurement, may help detect differences between alternative interventions for kidney 
transplant recipients, it was developed as an interview, which may preclude its use in 
several applications( Jacobs R. et al.,1998 ), and  provides more information than the SF-
36 (Rebollo, P., et al.,2003) . 
A mean score ranging from 1 to 7 is reported for each of the five domains of KTQ. A mean 
score ranging from 1 to 3.5 is reported to be low(a lot of discomfort) while above 3.5 is 
moderate(a moderate degree of discomfort) while more than 5 is high QoL(a little degree 
or no of discomfort). To calculate the score of each dimension the sum of all the items in 
the dimension is determined and then divided by the number of items in that dimension, 
with higher scores representing better functioning. 
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The author of the KTQ were contacted to obtain the English version of KTQ ,which was 
translated into Arabic by experts after a permission of the author, after that the translated 
Arabic questionnaire was back translated to English by other experts to be compared with 
original copy to make sure that the questions have the same meaning.  
Modifications to the Arabic versions were made by 3 clinical pharmacy research experts 
and two pharmacy graduate students, finally the last Arabic version of the questionnaire 
was reviewed by a doctor and nurses of dialysis unit in Biet Jala governmental Hospital in 
the city of Bethlehem. 
2.3 Study population & Sample Size  
According to the MOH recordings the average number of kidney transplant patients in 
primary healthcare clinics of Bethlehem was 70 and North Hebron (Halhoul) was 46 
kidney transplant patients.  
Sample size according to the inclusion criteria was 109 patients in both central clinics. 
Therefore the sample size includes most of the patient population in those two regions it 
was a convenient sample.  
In this study our goal was to choose Bethlehem and Hebron, unfortunately there was a lack  
of recording for these patients in middle and south Hebron, patients in these two areas were 
distributed into many clinics which were very difficult to reach on the opposite of 
Bethlehem and North Hebron which were central clinics and easy to reach.   
3.3 Study design   
This study was designed as descriptive, non experimental, cross sectional health status 
study of Quality of life for kidney transplant patients  
4.3 Study setting 
This study was conducted particularly at the  Ministry of Health primary healthcare clinics 
of Bethlehem and north Hebron in Palestine.  
23 
 
5.3 Inclusion criteria  
The inclusion criteria for the recipients were as follows:  
1) Kidney transplant patients aged more than 20 and less than 71 years of age.  
2) Patients get follow up in primary healthcare clinics of Bethlehem and northern of 
Hebron in Palestine.  
3)  Patients have a functioning kidney (free from dialysis). 
4) More than 3 months post-transplant(after the acute phase of transplant). 
6.3 Period of the study  
The data was collected between December 2016 and April 2017. 
7.3 Data collection 
The interviews were conducted for patients who met the study inclusion criteria at a private 
room in the clinics while the patients came in to receive their monthly medication from the 
pharmacy of primary healthcare clinics of Bethlehem and north Hebron, first introduced 
myself and stated the purpose of the study. Some interviews were conducted at home after 
calling the patients by phone and asking their permission because many of the patients 
depended on their relatives to get medication every month from the clinics. We used face 
to face method to collect the data. The questionnaire took about 15 to 20 minutes to 
complete, the short time required makes the questionnaire suitable for everyday clinical 
use. 
7.4 Data Analysis 
Data was analyzed by using SPSS statistical analysis program version 19.Results were 
reported as mean ± standard deviation, minimum value, maximum value, frequencies and 
percentages,  of all socio-demographic characteristics. The association between socio-
demographic factors and QOL domains was examined using one-way analysis of variance 
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ANOVA  and t-Test for Independent variables. A P-value of 0.05 or less was considered to 
indicate statistical significance. 
 Confidence intervals were calculated at the 95% level of confidence. 
 To determine the QoL from KTQ results for each dimension the sum of all the items in the 
dimension is determined and then divided by the number of items in that dimension.  
 
This questionnaire has been demonstrated to have good validity and reliability in many 
previous studies (Rebollo, P., et al.,2003, Tayyebi A. et al. 2012, Chisholm-Burns, M.A., 
et al.,2011)  
8.4 Ethical Considerations 
Ethical approval for the study was obtained from the Research Ethics Committee in Al-
Quds University and the Ministry of Health (appendix 3).    
Permission for translation of the questionnaire was asked from Laupacis (the author of 
KTQ questionnaire). All patients were first asked if they are willing to participate in this 
interview and interview was done after they gave verbal consent, names of the patients 
were deleted after completing the interview. 
 
 
 
 
 
 
 
25 
 
 
Chapter 4 : Results 
1.4 Description of the KTQ-25 data of the participants 
The overall mean quality of life score for kidney transplant patients was 4.02±0.84,which 
indicates that the patients in our sample population have a moderate degree of discomfort 
after undergoing the renal transplantation. The highest score of the KTQ was found in the 
appearance dimension(5.40±1.23)which suggests that patients suffered from some 
discomfort, while the lowest score in this study was related to the uncertainty/fear 
dimension (3.36±1.23)which implies that patients suffered a lot of discomfort after 
undergoing the renal transplantation. Physical Symptoms dimension (3.55±0.94), this 
means that patients have a moderate degree of discomfort, the same moderate degree was 
found in the fatigue(4.06±1.30) and emotional(3.78±1.32) dimensions(Table2). 
Table 2:The average quality of life scores based on KT questionnaire 5 dimensions(One-
Sample Description Statistics) whereby N=109.  
Dimension N Minimum Maximum 
Mean 
QoL 
Std. 
Deviation 
Std. Error 
Mean 
Physical 
Symptoms 
109 1 6 3.55 0.943 0.090 
Fatigue 108 1 7 4.06 1.297 0.125 
Uncertainty 
/Fear 
109 1 6 3.36 1.225 0.117 
Appearance 109 2 7 5.40 1.234 0.118 
Emotional 108 1 7 3.78 1.320 0.127 
Valid N (list 
wise) 
108      
QoL: Quality Of Life , std: standard, N:number 
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SPSS Statistics Output for Cronbach's Alpha 
2.4 Reliability Statistics 
The coefficient alpha (or Cronbach’s alpha) was used to assess the internal 
consistency of the KTQ. The alpha value was 0.74which indicates that the KTQ is 
a reliable test. 
 
Table 3: The Reliability Statistics table that provides the actual value for Cronbach's 
alpha. 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's Alpha Based on Standardized Items N of Items 
0.732 0.741 5 
 
N :number 
Table 4 below describes the value that Cronbach's alpha would be if that particular item 
was deleted from the scale. We can see that removal of any dimension, except 
Appearance, would result in a lower Cronbach's alpha. Therefore, removal of the 
Appearance dimension would lead to a small improvement in Cronbach's alpha, the 
"Corrected Item-Total Correlation" value was low(0.220) for this item. 
Table 4: The average quality of life scores based on KT questionnaire 5 dimensions Item-
Total Statistics 
Dimension 
Scale 
Mean if 
Item 
Deleted 
Scale 
Variance 
if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if 
Item 
Deleted 
Physical 
Symptoms 
16.60 12.730 0.615 0.479 0.655 
Fatigue 16.08 10.846 0.613 0.515 0.635 
Uncertainty 
Fear 
16.78 11.480 0.571 0.370 0.654 
Appearance 14.74 14.173 0.220 0.091 0.785 
Emotional 16.35 11.411 0.516 0.348 0.677 
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3.4 One Sample t-Test 
As shown in table 5, the one-sample t-test is used to determine whether a sample comes 
from a population with a specific mean. This population mean is not always known, but 
sometimes it is hypothesized. 
According to the value p<0.05 for the Physical Symptoms dimension is (P =0.000), the 
Physical Symptoms dimension has significant statistical effects on QoL, and 
consequently negatively affects the patients. 
The t value = -5.029, p>0.05 for Fatigue dimension (P =0.636), so it has no statistical 
significant impact on QoL. 
While for Uncertainty/Fear dimension P<0.05 (p =0.000); statistically there is a 
significant impact on QoL and it negatively affects the patients where t value = -5.491. 
The p<0.05 in the Appearance dimension (p =0.000),so it can be concluded that the 
Appearance dimension has statistical significant impact on QoL and positively affects the 
patients where t value = 11.859. 
Finally, the Emotional dimension value of p >0.05 (p =0.092) suggesting that the 
emotional dimension has no significant statistical effect on QoL.  
 
Table 5: Statistical results of the one-sample t-Test whereby the test value =4.  
Dimension T df 
Sig. (2-
tailed) 
Mean 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Physical 
Symptoms 
-
5.029 
108 0.000 -0.454 -0.63 -0.28 
Fatigue 0.475 107 0.636 0.059 -0.19 0.31 
Uncertainty 
Fear 
-
5.491 
108 0.000 -0.644 -0.88 -0.41 
Appearance 
11.85
9 
108 0.000 1.401 1.17 1.64 
Emotional 
-
1.701 
107 0.092 -0.216 -0.47 0.04 
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4.4 Description of the socio-demographic data of the participants: 
The study participants were 109 kidney transplant patients; 64 patients from Bethlehem 
representing 58.7% of the sample and 45 patients from North Hebron representing 41.3%of 
the sample (Table 6). 
 
Table 6: Description of regions 
Region Frequency Percent Valid Percent 
Cumulative 
Percent(%) 
Bethlehem 64 58.7 58.7 58.7 
North Hebron 45 41.3 41.3 100.0 
Total 109 100.0 100.0  
 
Most of the kidney transplant recipients were male with a percentage of 79.8%whereas 
females comprised 20.2% (Table 7). 
 
Table 7: percent of kidney transplant recipients by gender.  
Gender Frequency Percent Valid Percent 
Cumulative 
Percent 
Female 22 20.2 20.2 20.2 
Male 87 79.8 79.8 100.0 
Total 109 100.0 100.0  
  
Figure 1 below shows the demographic distribution of male and female participants for 
both Bethlehem and North Hebron. The proportion of women in Bethlehem was 10.09% 
and that of men was 48.62%,while in North Hebron the proportion of women was 10.09% 
and 31.19% men.  
 
29 
 
 
Figure 1: Visual representation of the distribution of participants by gender by 
district. 
In table 8 below patients were between 20-71 years of age, and their mean age was 41±24 
years. 7.3% of the patients are less than25 years old, 37.6% of whom are classified under 
the second class (26-40)years while most of them are classified under the third class (41 - 
65)years with 50.5%,only 4.6% of patients are above 65 years old.  
 
Table 8: percent distribution of participants by age. 
Age Range Frequency Percent Valid Percent 
Cumulative 
Percent 
< 25 8 7.3 7.3 7.3 
26 - 40 41 37.6 37.6 45.0 
41 - 65 55 50.5 50.5 95.4 
≥ 65 5 4.6 4.6 100.0 
Total 109 100.0 100.0 
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Most of the patients were married with a proportion of 81.7%, while 0.9% were widowed 
and the rest 17.4% were unmarried(Table 9). 
Table 9: Description of Marital Status 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Married 89 81.7 81.7 81.7 
Unmarried 19 17.4 17.4 99.1 
Widowed 1 .9 .9 100.0 
Total 109 100.0 100.0  
 
Table 10 shows the results in relation to the educational level. Most of the patients 
completed college degree with (32.1%),29.4% completed high school,12.8% obtained a 
diploma and only11.9% of patients finished primary school, the same percent was with 
middle school and only 2 patients(1.8%)had no formal education. 
 
 Table 10: Description of Educational level 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
I did not learn any 
formal education 
2 1.8 1.8 1.8 
Primary school 13 11.9 11.9 13.8 
Middle school 13 11.9 11.9 25.7 
High school 32 29.4 29.4 55.0 
Diploma 14 12.8 12.8 67.9 
College degree 35 32.1 32.1 100.0 
Total 109 100.0 100.0  
 
 
Regarding the job status of the patients as shown in Table 11 below, the majority of 
subjects  don't work reaching 45.9%of the sample, 28.4% were private employees,9.2 
%work in the private sector,11.9% were government employees, and 4.6 % of patients 
were retired. 
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Table 11: Description of Job Status 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Private sector  10 9.2 9.2 9.2 
Government 
employee 
13 11.9 11.9 21.1 
Retired 5 4.6 4.6 25.7 
Private Employer 31 28.4 28.4 54.1 
Do not work 50 45.9 45.9 100.0 
Total 109 100.0 100.0  
 
while in table12 income level for 53.2% of patients was less than 1500NIS while 32.1% of 
patients are classified under the second class (1500 – 3000NIS), and only14.7% of patients 
had an income of more than 3000NIS per month. 
Table 12: Description of Income Level 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Less than 1500 NIS 58 53.2 53.2 53.2 
From 1500 - 3000 
NIS 
35 32.1 32.1 85.3 
More than 3000 NIS 16 14.7 14.7 100.0 
Total 109 100.0 100.0  
 
Description of the clinical data of the participants: 
When the patients were asked if they smoked or not, the vast majority of patients 
(85.3%)said they were non-smokers while about 14.7% were smokers(Table 13). 
 
Table 13: Description of the question: Are you smoker? 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
No 93 85.3 85.3 85.3 
Yes  16 14.7 14.7 100.0 
Total  109 100.0 100.0  
 
Patients were also asked about disease conditions before their kidney transplant that may 
have contributed to ESRD and the result was that 18.3%of patient’s ESRD was due to 
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hypertension, 10.1% was due to diabetic nephropathy, 15.6% due to Glomerulonephritis 
while the same percent 15.6% of the patient’s ESRD was due to cystic kidney disease. 
Surprisingly, 47.7% of patients in our sample attributed ESRD to other reasons (Table 14). 
 
 Table 14: Cause of ESRD Description 
Cause of ESRD (Hypertension) 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
No 89 81.7 81.7 81.7 
Yes  20 18.3 18.3 100.0 
Total  109 100.0 100.0  
Causes of ESRD (Diabetic nephropathy) 
No 98 89.9 89.9 89.9 
Yes  11 10.1 10.1 100.0 
Total  109 100.0 100.0  
Causes of ESRD (Glomerulonephritis) 
No 92 84.4 84.4 84.4 
Yes  17 15.6 15.6 100.0 
Total  109 100.0 100.0  
Causes of ESRD (Cystic kidney disease) 
No 92 84.4 84.4 84.4 
Yes  17 15.6 15.6 100.0 
Total  109 100.0 100.0  
Causes of ESRD (Other reasons) 
No 56 51.4 51.4 51.4 
Yes  52 47.7 47.7 99.1 
Total  1 0.9 0.9 100.0 
 
ESRD:  End-Stage Renal Disease 
 
The majority (66.1%) of Kidney Donor’s type were biologically blood related (father, 
mother, brother)while 21.1% were non-biological (spouse, life partner, friend, other),and 
10.1 % of the donors were Sibling (other relatives), but the number of cadaveric transplant 
patients which was one patient was too small to draw a valid conclusion about cadaveric 
recipients(Table 15). 
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Table 15: Description of Type of donor 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Cadaveric 1 0.9 0.9 0.9 
Living 2 1.8 1.8 2.8 
Biological, blood related 
(father, mother, brother) 
72 66.1 66.1 68.8 
Sibling, other relative 11 10.1 10.1 78.9 
Non-biological (spouse, life 
partner, friend) 
23 21.1 21.1 100.0 
Total 109 100.0 100.0  
 
As for immunosuppressive medications in our sample, the majority of kidney transplant 
patients 83.3. % used (prednisone), 45.4% used (Cyclosporine A/Neoral), 70.4% used 
mycophenolate mofetil (MMF).While 53.7% of the patients used Tacrolimus(Prograf) and 
only1.9% of the patients were used Sirolimus (rapamune) (Table 16). 
Table 16: Description of Anti-Rejection Medications to prevent Renal Failure 
Current Anti-Rejection Medications (Prednisone) 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
No  18 16.5 16.7 16.7 
Yes  90 82.6 83.3 100.0 
Total  108 99.1 100.0  
Current Anti-Rejection Medications (Cyclosporine A/Neoral) 
No  59 54.1 54.6 54.6 
Yes  49 45.0 45.4 100.0 
Total  108 99.1 100.0  
Current Anti-Rejection Medications (Mycophenolate Mofetil (Cellcept)) 
No  32 29.4 29.6 29.6 
Yes  76 69.7 70.4 100.0 
Total  108 99.1 100.0  
Current Anti-Rejection Medications (Tacrolimus(Prograf)) 
No  50 45.9 46.3 46.3 
Yes  58 53.2 53.7 100.0 
Total  108 99.1 100.0  
Current Anti-Rejection Medications (Sirolimus (rapamune)) 
No  106 97.2 98.1 98.1 
Yes  2 1.8 1.9 100.0 
Total  108 99.1 100.0  
Missing System 1 0.9   
Total 109 100.0   
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As shown in table 17 below, about 21.3%of the patients didn't have dialysis procedure 
before renal transplantation, while 52.8%of the patients did have less than one-year 
dialysis procedure, 13.9%of the patients did have from 1 - 2 years of dialysis and  
only12.0% of the patients did have more than 2 years dialysis. 
 Table 17: Description of the Duration of Dialysis Before Renal Transplantation 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Didn't have 
dialysis procedure 
23 21.1 21.3 21.3 
Duration of 
dialysis less than 
one year 
57 52.3 52.8 74.1 
Duration of 
dialysis is from 1 - 
2 Years 
15 13.8 13.9 88.0 
Duration of 
dialysis is more 
than 2 Years 
13 11.9 12.0 100.0 
Total 108 99.1 100.0  
Missing System 1 .9   
Total 109 100.0   
 
The majority of the patients88.9% made only one renal transplant while only 11.1% did 
more than one renal transplant(Table 18); while according to the time passed from 
transplantation only3.7% of the patients performed the renal transplant within less than 1 
year, while 24.1%performed the renal transplant before 1 to 5 years, most of the patients 
38.9%performed the renal transplant before 6 to 10 years ago, 21.3% of the patients 
performed the renal transplant before 11 to 15 years and 12% of the patients performed the 
renal transplant before more than 15 years. 
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Table 18: Description of the question: Have you undergone more than one renal 
transplant? and the date of your last renal transplant? 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
No 96 88.1 88.9 88.9 
Yes 12 11.0 11.1 100.0 
Total 108 99.1 100.0  
Missing System 1 .9   
Total 109 100.0   
What is the date of your last renal transplant? 
 
Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 
< 1 4 3.7 3.7 3.7 
1 - 5 26 23.9 24.1 27.8 
6 - 10 42 38.5 38.9 66.7 
11 - 15 23 21.1 21.3 88.0 
≥15  13 11.9 12.0 100.0 
Total 108 99.1 100.0  
Missin
g 
System 1 0.9   
Total 109 100.0   
 
 
The most common physical problems that faces the patients after renal transplantation 
was aching and tired legs (68.8%) followed by very little strength (61.5%), aching bones 
(60.6%), muscle pain (52.3), while only 7.3% experienced decreased sexual ability 
followed by regulating bowel movements (10.1%), difficulty focusing attention(11%), 
loss of appetite(16.5%) and vomiting (17.4%), and other physical problems as shown in 
Table 19. 
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Table 19: Description of all Physical Problems of Symptoms Characteristics 
Problems of Symptoms Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
Loss of weight and 
muscle 
No 82 75.2 75.2 75.2 
Yes 27 24.8 24.8 100.0 
Total 109 100.0 100.0  
 
 
Decreased mental 
ability 
No 89 81.7 81.7 81.7 
Yes 20 18.3 18.3 100.0 
Total 109 100.0 100.0  
 
 
Itchy / dry skin 
No 76 69.7 69.7 69.7 
Yes 33 30.3 30.3 100.0 
Total 109 100.0 100.0  
 
 
Infections 
No 63 57.8 57.8 57.8 
Yes 46 42.2 42.2 100.0 
Total 109 100.0 100.0  
 
 
Hypotension 
No 88 80.7 80.7 80.7 
Yes 21 19.3 19.3 100.0 
Total 109 100.0 100.0  
 
 
Embarrassed by 
appearance or access 
site 
No 86 78.9 78.9 78.9 
Yes 23 21.1 21.1 100.0 
Total 109 100.0 100.0  
 
 
Aching, tired legs 
No 34 31.2 31.2 31.2 
Yes 75 68.8 68.8 100.0 
Total 109 100.0 100.0  
 
 
Coughing during day 
or night 
No 73 67.0 67.0 67.0 
Yes 36 33.0 33.0 100.0 
Total 109 100.0 100.0  
 
 
Very little strength 
No 42 38.5 38.5 38.5 
Yes 67 61.5 61.5 100.0 
Total 109 100.0 100.0  
 
 
Side-effects from 
medications 
No 67 61.5 61.5 61.5 
Yes 42 38.5 38.5 100.0 
Total 109 100.0 100.0  
 
Forgetfulness No 60 55.0 55.0 55.0 
Yes 49 45.0 45.0 100.0 
Total 109 100.0 100.0  
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Confusion 
No 61 56.0 56.0 56.0 
Yes 48 44.0 44.0 100.0 
Total 109 100.0 100.0  
 
 
Aching bones 
No 43 39.4 39.4 39.4 
Yes 66 60.6 60.6 100.0 
Total 109 100.0 100.0  
 
 
Trouble getting to 
sleep 
No 73 67.0 67.0 67.0 
Yes 36 33.0 33.0 100.0 
Total 109 100.0 100.0  
 
 
Regulating bowel 
movements 
No 98 89.9 89.9 89.9 
Yes 11 10.1 10.1 100.0 
Total 109 100.0 100.0  
 
 
Constipated or having 
diarrhea 
No 75 68.8 68.8 68.8 
Yes 34 31.2 31.2 100.0 
Total 109 100.0 100.0  
 
 
Vomiting 
No 90 82.6 82.6 82.6 
Yes 19 17.4 17.4 100.0 
Total 109 100.0 100.0  
 
 
Headaches 
No 65 59.6 59.6 59.6 
Yes 44 40.4 40.4 100.0 
Total 109 100.0 100.0  
 
 
Nausea or upset 
stomach 
No 66 60.6 60.6 60.6 
Yes 43 39.4 39.4 100.0 
Total 109 100.0 100.0  
 
 
Shivering 
No 68 62.4 62.4 62.4 
Yes 41 37.6 37.6 100.0 
Total 109 100.0 100.0  
 
 
Waking up during the 
night 
No 63 57.8 57.8 57.8 
Yes 46 42.2 42.2 100.0 
Total 109 100.0 100.0  
 
 
Loss of appetite 
No 91 83.5 83.5 83.5 
Yes 18 16.5 16.5 100.0 
Total 109 100.0 100.0  
      
 
Lightheaded or dizzy 
during daily activities 
No 66 60.6 60.6 60.6 
Yes 43 39.4 39.4 100.0 
Total 109 100.0 100.0  
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Short of breath in daily 
activities 
No 61 56.0 56.0 56.0 
Yes 48 44.0 44.0 100.0 
Total 109 100.0 100.0  
 
 
Decreased sexual 
ability 
No 101 92.7 92.7 92.7 
Yes 8 7.3 7.3 100.0 
Total 109 100.0 100.0  
 
 
Difficulty focusing 
attention 
No 97 89.0 89.0 89.0 
Yes 12 11.0 11.0 100.0 
Total 109 100.0 100.0  
      
 
Difficulty 
concentrating 
No 85 78.0 78.0 78.0 
Yes 24 22.0 22.0 100.0 
Total 109 100.0 100.0  
 
 
Need to rest frequently 
because of shortness of 
breath 
No 77 70.6 70.6 70.6 
Yes 32 29.4 29.4 100.0 
Total 109 100.0 100.0  
      
 
Increase in appetite 
 
No 57 52.3 52.3 52.3 
Yes 52 47.7 47.7 100.0 
Total 109 100.0 100.0  
      
 
Excessive weight gain 
No 69 63.3 63.3 63.3 
Yes 40 36.7 36.7 100.0 
Total 109 100.0 100.0  
      
 
Acne 
No 85 78.0 78.0 78.0 
Yes 24 22.0 22.0 100.0 
Total 109 100.0 100.0  
 
Trouble getting a good 
night's sleep 
No 79 72.5 72.5 72.5 
Yes 30 27.5 27.5 100.0 
Total 109 100.0 100.0  
 
 
Muscle pain 
No 52 47.7 47.7 47.7 
Yes 57 52.3 52.3 100.0 
Total 109 100.0 100.0  
The relationship between demographic variables and the quality of life using Independent 
Sample t-Test and One-way ANOVA Test. 
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 In the study of the relationship between demographic variables and QoL scores, no 
significant differences are observed if the P values > 0.05 in ANOVA Test and > 0.01 in 
the independent sample t-Test as shown in table20.  
Residency: t-test was performed to evaluate the effect of residency on QoL, there was no 
significant relationship between residency and QoL (3.27 ± 0.782) in Bethlehem compared 
to QoL (3.48 ± 0.553) in North Hebron, t (106) = -1.493,p = 0.138.  
Gender: there was no significant effect between age and QoL score (3.3552 ± 0.679) for 
females compared to QoL score (3.36 ± .712) for males, t (106) = T= 0.008,p = 0.994. 
Age: according to one-way ANOVA test, there was no significant relationship between 
age and QoL (F (3,104) = 0.551, p = 0.648). 
Marital Status:one-way ANOVA test was performed to examine the relationship between 
marital status and QoL (F (2,105) = 3.505, p = 0.034). There was a significant effect of 
marital status on QoL, single patients had higher QoL than married ones.  
Education level: as a result of one-way ANOVA there was no significant relationship 
between education level and QoL (F (5,102) = 0.207, p = 0.959). 
Job status: there was no statistical significant differences between job status and QoL 
which was determined by one-way ANOVA (F (4,103) = 1.034, p = 0.393). 
Income Level: this was determined by one-way ANOVA (F (2,105) = 1.99, p = 0.141), 
there was no significant differences between income level groups and QoL. 
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Table 20: The relationship between demographic variables and QoL by using Independent 
Sample t-Test and One-way ANOVA Test 
Demographic Variable 
QoL 
Scores 
Statistical test 
Significant 
level 
Region 
Bethlehem (64) 3.27±.782 
T= -1.493 P = 
.138 
P < 0.01 
Hebron (44) 
3.48 ± 
.553 
T = -
1.590 
P = 
.115 
 
Gender 
Female (21) 
3.36 ± 
.679 
T= .008 
P = 
.994 
P < 0.01 
Male (87) 
3.36 ± 
.712 
T = .008 
P = 
.994 
 
Age 
< 25 
3.5861 ± 
.538 
Single-factor analysis 
of variance / f = .551 
and 
P = 0.648 
P < 0.05 
26 - 40 
3.3232 ± 
.617 
41 - 65 
3.3243 ± 
.617 
 
≥ 65  
3.6028 ± 
.649 
 
Marital 
Status 
Married (89) 3.31±.705 Single-factor analysis 
of variance / f = 
3.505 and 
P = .034 
P < 0.05 
Unmarried (18) 3.47±.581 
Widowed (1) 5.06±.000 
 
Education 
I did not learn 
any formal 
education 
3.5931 ± 
.893 
Single-factor analysis 
of variance / f = .207 
and  
P = 0.959 
P < 0.05 
Primary school 
3.1991 ± 
.745 
Middle school 
3.3241 ± 
.658 
High school 
3.3615 ±. 
.577 
Diploma 
3.3671 ± 
.698 
College degree 
3.4051 ± 
.834 
 
Job Status 
Private sector 
employee 
3.24 ± 
.855 
Single-factor analysis 
of variance / f = 
1.034 and   
P = .393 
P < 0.05 
Government 
employee 
3.57±.715 
Retired 3.57±.901 
Private Employer 3.47 ± 
.684 
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Do not work 3.24 ± 
.659 
 
Income 
Level 
Less than 1500 
NIS 
3.2327 ± 
.686 
 
Single-factor analysis 
of variance / f = 1.99 
and  
P = 0.14 
P < 0.05 
From 1500 - 3000 
NIS 
3.4860 ± 
.653 
More than 3000 
NIS 
3.5281 ± 
.815 
     
QoL: Quality Of Life 
The relationship between clinical variables and quality of life by using Independent 
Sample t-Test and One-way ANOVA Test. 
In the study of the relationship between some clinical variables and QoL scores no 
significant difference observed if the P values > 0.05 in ANOVA Test and > 0.01 in the 
independent sample t-Test as shown in table 21.  
Smoking: this study found that whether the patient is a smoker or not there was no 
significant difference on QoL (3.58 ± 0.787)smokers compared to (3.32 ± 0.684) non-
smokers, t (106) = 1.376, p = 0.172. 
Donor type: one-way ANOVA(F (4,103) = 0.532, p = 0.713)reported that there was no 
relationship between donor type  and QoL . 
 
Time after transplant: there was  no significant statistical difference between time after 
transplant (years) and QoL which was determined by one-way ANOVA (F (4,102) = 
0.755, p = 0.557). 
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Table 21: The relationship between clinical variables and QoL by using Independent 
Sample t-Test. 
 
Clinical 
variables 
 
QoL 
Scores 
Statistical 
test 
 
Significant 
level 
Are you smoker? 
Yes (16) 3.58±.787 T= 1.376 P = 
.172 
P < 0.01 
No (92) 3.32±.684 T = -1.246 P = 
.228 
 
Donor type 
Cadaveric 3.47 ±.000 
Single-factor 
analysis of 
variance / f = 
.532 and 
P = 0.713 
P < 0.05 
Living 4.04 ± .075 
Biological, 
blood related 
(father, 
mother, 
brother) 
3.33 ± .685 
Sibling, other 
relative 
3.42 ± .651 
Non-
biological 
(spouse, life 
partner, 
friend) 
3.35 ± .816 
 
Time after 
transplant(year) 
< 1 3.4569 ± .719 
Single-factor 
analysis of 
variance / f = 
.755 and 
P = 0.557 
P < 0.05 
1 – 5 3.1775 ± .670 
6 – 10 3.4169 ± .662 
 
11 – 15 
3.4710 ± .750 
≥15  3.4476 ± .603 
 
 
 
In the study of the relationship between these clinical variables and QoL scores no 
significant difference observed if the P values > 0.01 in the independent sample t-Test 
shown in table 22. 
 
Anti-Rejection Medications results: In our study there was no significant difference 
between the anti-rejection medications used and QoL scores. 
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 If patients used Prednisone or not there was no significant difference on QoL 
score (3.36 ± 0.701) for patients who were using Prednisone compared (3.47 ± 
0.544) with patients who didn’t, t (105) = -0.657, p = 0.513. 
 QoL scores for patients using Cyclosporine A/Neoral or not had no significant 
difference on QoL score (3.48 ± 0.672) for patients who were using 
Cyclosporine A/Neoral compared to QoL score (3.29 ± 0.673) for patients who 
didn’t use Cyclosporine A/Neoral, t (105) = 1.448, p = 0.151. 
 Patients using Mycophenolate Mofetil (Cellcept) had no statistical significant 
difference on QoL score (3.32 ± 0.683) for patients who were using 
Mycophenolate Mofetil (Cellcept) compared to QoL score (3.51 ± 0.651) for 
patients who didn’t use Mycophenolate Mofetil (Cellcept),t (105) = 1.334, p = 
0.185. 
 The patients using Tacrolimus(Prograf) had no significant difference on QoL 
score (3.38 ± 0.652) for patients who were using Tacrolimus(Prograf) compared 
to QoL score (3.37± 0.709) for patients who didn’t use Tacrolimus(Prograf) ,t 
(105) = 0.017, p = 0.987. 
 This study found that whether the patient used Sirolimus (rapamune) or not, 
there was no significant difference on QoL score (3.38 ± 0.652) for patients 
who were using Sirolimus (rapamune) compared to QoL score (3.37± 0.709) 
for patients who didn’t use Sirolimus (rapamune), t (105) = -0.060, p = 0.953. 
 This study found that whether the patient used the triple therapy (Prednisone+ 
Mycophenolate Mofetil (Cellcept)+ Tacrolimus(Prograf) )or not there  was no 
statistically significant difference for QoL score. (33.36 ± 0.725) to the patients 
do not use the triple therapy (Prednisone+ Mycophenolate Mofetil (Cellcept)+ 
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Tacrolimus(Prograf)  compared to QoL score (3.36 ± 0.667) to patient use the 
triple therapy. 
 
Causes of Renal Failure results: 
In our study there was no significant statistical relationship between the cause of ESRD 
and QoL score indicted even if renal failure happened because of hypertension or diabetes, 
nephropathy, Glomerulonephritis, Cystic kidney or other reasons. There was no significant 
difference on QoL score of patients who had this cause respectively (3.23 ± 0.651, 3.33 ± 
0.994, 3.26 ± 0.684, 3.46 ± 0.674 and 3.36 ± 0.901) compared to QoL score of patients 
who didn't have this cause (3.39 ± 0.714, 3.36 ± 0.668,3.37 ± 0.708,3.34 ± 0.709, 3.34 ± 
0.901). P = (0.357,0.886,0.568,0.505,.901),P=(0.335,0.918,0.564,0.496,0.901)respectively. 
Undergone more than one renal transplant or not: 
In this study there was no significant difference in QoL score with relation if patients had 
more than one renal transplant or not, QoL score was(3.36 ± 0.580) for patients who had 
more than one renal transplantation compared to QoL score (3.38 ± 0.690) for patients who 
didn’t have more than one renal transplantation, t (105) = -0.088, - 0.101,p= 0.930, 0.920, 
respectively. 
 
Co-morbid disease 
This study found that whether the patient had Hypertension and/ or Diabetic( 22.94%) or 
not (77.06%)there was no statistically significant difference for QoL score (3.23 ± .780) 
compared to QoL score (3.39 ± .678) for patients who didn’t have theses disease. 
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Table 22: The relationship between clinical variables and QoL by using Independent 
Sample t-Test. 
Clinical variables 
QoL 
Scores 
  
1. Anti-Rejection Medications 
Prednisone Yes 
(89) 
3.36 ± 
0.701 
T= -
0.657 
P = 
0.513 
P < 
0.01 
No 
(18) 
3.47 ± 
0.544 
T = -
0.777 
P = 
0.443 
 
Cyclosporine A/Neoral Yes 
(49) 
3.48 ± 
0.672 
T= 
1.448 
P = 
0.151 P < 
0.01 No 
(58) 
3.29 ± 
0.673 
T = 
1.448 
P = 
0.151 
     
Mycophenolate Mofetil (Cellcept) 
Yes 
(75) 
3.32 ± 
0.683 
T= -
1.334 
P = 
0.185 P < 
0.01 No 
(32) 
3.51 ± 
0.651 
T = -
1.360 
P = 
0.179 
 
Tacrolimus(Prograf) Yes 
(57) 
3.38 ± 
0.652 
T= 
0.017 
P = 
0.987 P < 
0.01 No 
(50) 
3.37± 0.709 T = 
0.017 
P = 
0.987 
 
Sirolimus (rapamune) Yes 
(2) 
3.35 ± 
0.460 
T= -
0.060 
P = 
0.953 P < 
0.01 No 
(105) 
3.38 ± 
0.681 
T= -
0.087 
P = 
0.944 
Triple Therapy (Prednisone+ 
Mycophenolate Mofetil 
(Cellcept)+ Tacrolimus(Prograf) ) 
No 
(70) 
3.36 ± 
0.725 
T= -
.020 
P 
=.984 P < 
0.05 Yes 
(38) 
3.36 ± 
0.667 
T= -
.020 
P 
=.984 
 
2. Causes of Renal Failure  
Hypertension 
Yes 
(20) 
3.23 ± 
0.651 
T = -
0.925 
P = 
0.357 P < 
0.01 No 
(88) 
3.39 ± 
0.714 
T = -
0.980 
P 
=0.335 
 
Diabetic nephropathy 
Yes 
(11) 
3.33 ± 
0.994 
T = -
0.143 
P = 
0.886 P 
<0.01 No 
(97) 
3.36 ± 
0.668 
T = -
0.105 
P = 
0.918 
 
Glomerulonephritis 
Yes 
(16) 
3.26 ± 
0.684 
T = -
0.572 
P = 
0.568 P < 
0.01 No 
(92) 
3.37 ± 
0.708 
T = -
0.586 
P = 
0.564 
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Cystic kidney disease 
Yes 
(17) 
3.46 ± 
0.674 
T = 
0.668 
P = 
0.505 P < 
0.01 No 
(91) 
3.34 ± 
0.709 
T = 
0.692 
P = 
0.496 
 
Other reasons 
Yes 
(52) 
3.36 ± 
0.901 
T = 
0.125 
P = 
0.901 P < 
0.01 No 
(55) 
3.34 ± 
0.901 
T = 
0.125 
P = 
0.901 
 
3. Have you undergone more than one renal transplant 
Have you undergone more than 
one renal transplant 
Yes 
(12) 
3.36±0.580 T= -
0.088 
P = 
0.930 P < 
0.01 No 
(95) 
3.38±0.690 T =-
0.101 
P = 
0.921 
triple therapy (Prednisone+ 
Mycophenolate Mofetil 
(Cellcept)+ Tacrolimus(Prograf) ) 
No 
(70) 
3.36 ± 
0.725 
T= -
.020 
P 
=.984 P < 
0.05 Yes 
(38) 
3.36 ± 
0.667 
T= -
.020 
P 
=.984 
 
Patients with  (Hypertension + 
Diabetic nephropathy) 
No 
(83) 
3.39±.678 T= 
1.010 
P = 
.315 P < 
0.05 Yes 
(25) 
3.23±.780 T= 
.936 
P = 
.355 
 
QoL: Quality Of Life 
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Chapter 5 : Discussion  
 
In this chapter we will discuss the study findings and their implications. This study 
focuses on determining QoL among renal transplant patients and  the effect of socio-
demographic variables on the QoL of these patients. 
 
1.5 Health -related Quality of life of kidney transplant patient 
1.1.5 Dissection of Kidney Transplant Questionnaire results 
In our study, the mean quality of life for our patients was moderate 4.02±0.84 which was 
considerably lower than that of Rebollo et al. in Spain (5.58), Chisholm-Burns et al. in 
USA (5.5), Tayyebi et al. in Iran (4.9) and a Chinese study (4.8) but also arguably higher 
than Rostami et al. in Iran (2.8) while all of them were using KTQ instrument. It is worthy 
to note that all the studies mentioned used the same questionnaire (KTQ). In our study the 
highest score was related to the dimension of body appearance (5.40±1.234) which agrees 
with all mentioned previous studies with the exception of Rostami et al. whose highest 
score was that of fear and uncertainty. 
The lowest score in this study was the fear/uncertainty (3.36±1.225) dimension which was 
consistent with the studies done by Tayyebi et al. in Iran and the Chinese study. 
Internationally,  the lowest score was that of the physical symptoms in both of Rebollo et 
al. in Spain , Chisholm-Burns et al. in USA. The study of Rostami et al. in Iran had the 
lowest score in the emotional item. 
Fear of rejection and uncertainty about the future were the chief concerns of the kidney 
transplant recipients which can be indicative of high rates of anxiety and stress particularly 
regarding graft rejection and resuming dialysis especially that these  patients had bad 
memories about dialysis(de Brito, D.C.S., et al., 2015) which illustrates the need for 
psychological consultation, support before and immediately after the transplant surgery 
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and maintaining it up at regular intervals. In our study, most of the recipients had receive 
kidney from a relative (a parent or a sibling) which varies from the other studies from other 
countries which suggested that the recipients had different feelings of fear, stress and guilt 
about the donors, which in turn affect their quality of life. 
 
2.1.5 Dissection of socio-demographic characteristics  
Our results showed no significant difference for the following socio-demographic and 
clinical variables include: residency, gender, age, education level, job status( employment), 
income level, donor type, immunosuppressive therapy, time after transplant, duration of 
dialysis before renal transplantation ,causes of ESRD, physical problems, if undergone 
more than one renal transplant and smoking, while the significant difference for Marital 
status on QoL only. 
3.1.5 Residency  
There was no difference in QOL between patients lives in Bethlehem 3.9276 ±0.94 or in 
North Hebron 4.14±1.24 both of QoL was moderate.   
 
4.1.5 Gender 
In this study, the sample consisted of 79.8% male and 20.2% female this is consist with 
many studies that prevalence of chronic kidney disease increased significantly in men not 
in women (Nagata et al., 2010), There was a predominance of males, representing 79.8% 
of the sample, which consists with the Brazilian study done by Costa and Nogueira (2014). 
There was no significant difference between gender (male, female) and QoL in our sample.   
the study of Junchotikul P et al( 2015)  is consistent with our results that gender was not 
significantly correlated with quality of life. Several other studies were inconsistent with 
our result and showed that gender has a significant effect on the QoL with  higher QoL for 
men(Sa’ed, H.Z., et al., 2016, Tayebi, A., et al., 2010, Kamran, F.2013). 
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5.1.5 Age 
In our study, the mean age was 41±24 years, ranging from 20-71 years old which 
establishes that most kidney transplant recipients were at a productive stage of their lives, 
only 4.6 % of patients were above 65years.  
There was no significant difference between patient’s age groups and QoL which is 
consistent with many studies [42, 50]. There were no QoL differences between transplant 
patients under and over 65 years of age, these findings were quiet similar to those reported 
by Laupacis et al. (1996). also result report by Hedayati et al. (2016)consist with our 
results.. This was consistent with the study by Gentile et al. (2013). However, the findings 
of the present study were inconsistent with results reported by Gentile et al. (2013), 
Tayyebi et al. (2010) and  Zyoud et al. (2016) which found that age has a significant 
negative effect on QoL because of the aging process and its complications.  
6.1.5 Education level  
In this sample the level of education has no significance effect on QoL of KT patients, the 
same result was reported by Lemos et al. (2015).  In contrast to our result, many studies 
have linked higher educational level with better QoL (Sa’ed, H.Z., et al.,2016, Gentile, S., 
et al.,2013) .It was expected that educated patients would have more information and 
understanding about their illness with good communication with medical staff, many 
studies found that patients who had low knowledge about the disease process had poor 
QoL scores. 
7.1.5 Income level  
In our study there was no significant effect of income level on QoL. Many studies disagree 
with our results which was reported by Junchotikul et al. (2015), and Lemos et al. (2015), 
which state that family income was the most important factor affecting QoL. Finances are 
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a major concern for the recipients because of expensive immune-suppressant medications 
and the compliance with regular follow-ups post transplant.  
8.1.5 Job status 
This study points out that there were no significant differences between groups of 
employment and QoL. Interestingly, a study done by (Kamran, F. 2012 ) investigated the 
impact of depression levels on satisfaction with QoL after renal transplantation, no 
significant differences in depression levels were found among recipients based on their 
work status . To the contrast, one study indicated that employed recipients were in better 
condition compared with unemployed recipients, which is stated by (Neipp et al. 2006). 
Furthermore, Gabriele Helga Franke found that employment was the strongest indicator of 
a high QoL (Franke et al., 1999) 
9.1.5  Marital status  
This study showed that there is a significant effect of marital status on QoL, single patients 
has better QoL  than married patients, this result could be explained that single patients live 
with their family; most of them experience good support from family ties in the traditional 
Palestinian culture. Family is the first support system for the single patients, parents 
usually takes the sick person to the hospital and works closely with the healthcare team to 
provide the best treatment and support, while married patients have many responsibilities 
towards their health and families. It should be noted that other studies indicated that 
married patients showed significantly better QOL than single patients, indicating that 
patients experience good support from their spouses and children (Ogutmen et al., 2006). 
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2.5 Dissection of clinical characteristics  
 
1.2.5 Immunosuppressive therapy 
Findings of the present study revealed that there was no relationship between QoL and the 
choice  
of immunosuppressive therapy. Recipients in our sample received triple therapy with 
corticosteroids, a calcineurin inhibitor (either tacrolimus or cyclosporine A), and 
mycophenolate mofetil (MMF). Some individuals are now treated with sirolimus, there 
were no differences in the evolution of the QOL with the therapies used which consist with 
the study of Rosa Jofre´, MD (Jofre, López-Gómez, Moreno, Sanz-Guajardo, & 
Valderrábano, 1998)Several studies demonstrate the superiority of some 
immunosuppressive regimens over others in the QOL domain. In other studies Tacrolimus 
has been shown to be associated with better QOL than cyclosporine (ciclosporin), as has 
corticosteroid-free immunosuppressive regimens (Perlman R. and Rao P,2014) .Physical 
activity, energy and appearance are important domains that are influenced by the 
mandatory immunosuppressive regimen (Fiebiger, W., C. Mitterbauer,2004).  
Also patients used the triple therapy (Prednisone+ Mycophenolate Mofetil (Cellcept)+ 
Tacrolimus(Prograf) ) had no significant effect on QoL. 
It is well-established that  poor adherence predicted worse outcomes: patients who were 
considered as delaying, skipping or altering their medication twice a month in the first year 
after kidney transplantation were more likely to lose their graft or to die during the follow-
up (Butler J. et al. ,2004). 
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2.2.5 Physical problems 
The most common physical problem in our study sample population was aching and tired 
legs about(75) 68.8% of the sample. this result agrees with the findings of Rostami, S.-
A.(2011),that this physical problem was seen  in 55% of subjects (Mersal & Aly, 2014). 
While the lowest common problem was the decreased of sexual ability ,many studies 
reported that sexual desire was increased significantly after kidney transplantation, but 
about 25% of men and women remained sexually dysfunctional (Schover, Novick, 
Steinmuller, & Goormastic, 1990),in general sexuality  was remarkably stable over the 1-
year after kidney transplant (Muehrer & Becker, 2005). 
Co-morbid disease 
The present study revealed that co-morbidity didn’t have any effect on QoL scores 
patient had Hypertension and/ or Diabetic or not there was no statistically significant 
difference for QoL , however patients who were without these disease had a slightly higher 
QoL even its not significant effect. 
 
3.2.5 Time after transplant  
There was no observed statistical significant difference between the time that passed from 
transplantation and QOL scores. Our result is consist with result of Tayyebi et al. 
(2010).Only 3.7% of the patients performed the renal transplant before less than 1 year 
,this small percentage could be explained that we excluded recipients less than 3 months 
post-transplant(after the acute phase of transplant).  
 
4.2.5 Duration of Dialysis Before Renal Transplantation  
No significant difference was observed between Duration of Dialysis Before Renal 
Transplantation groups and QoL ,while other studies reported that longer times spent on 
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dialysis were associated with lower QoL after transplantation (Griva K. et al.,2002). and 
influence on the accelerated ageing of the transplanted kidney( Domański L. et al.,2015).  
 
5.2.5 Smoking 
No significant difference was observed on the QoL between smokers or nonsmokers, while 
the majority of our sample were nonsmoker (85.3%). On the other hand, a health survey 
conducted in Norway showed that smoking, was significantly associated with 
ESRD(Hallan et al., 2006). 
6.2.5 Have you undergone more than one renal transplant 
No significant difference was observed between the two groups that undergone more than 
one renal transplant or not,  however, most of the patients (88.1%) did not have more than 
one renal transplant. 
7.2.5 Causes of ESRD  
In our study patients were asked about disease conditions before kidney transplant that 
may have contributed to ESRD 18.3% had hypertension while 10.1% had diabetic 
nephropathy. Surprisingly, 47.7% of patients in our sample was attributed ESRD to (other 
reasons) which is higher than the range worldwide (5–20%)( Boon N. et al.2006) .This 
result disagreed with results obtained from studies in Palestine; showed that hypertension 
and diabetes mellitus were the most common causes of ESRD(Sweileh, Sawalha, Sa'ed, 
Al-Jabi, & Shraim, 2009), the same results  reported by (Sayej and Qtait 2016) study in 
Hebron and Bethlehem.According to Kahder’s distribution by cause, most of patients were 
diabetic (22.5%), hypertensive (11.1%), or both diabetic and hypertensive at the same time 
(10.6%),  and there were a considerable number of patients where the cause was unknown 
(27.6%) (Khader, Snouber, Alkhatib, Nazzal, & Dudin, 2013), another study in Saudi 
Arabia was conducted to determine causes of ESRD showed that main causes of (ESRD) 
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include diabetic nephropathy(28%), hypertension(24%), unknown(23%) (Shaheen & Al-
Khader, 2005),  and a study was conducted in Egypt showed that hypertension was 
responsible for most of the cases of renal failure in Egypt. Other significant causes were: 
chronic Glomerulonephritis and ESRD of unknown etiology (Afifi & Karim, 1999). 
 
8.2.5 Donor type 
The number of cadaveric transplant patients was too small to draw a valid conclusion on 
the impact of donor type (cadaveric or living ) on QoL. However, there was no effect  in 
this study on the three types of  donors  (Biological: blood related  (father, mother or 
brother), other relatives or Non-biological donors) and the quality of life scores. Many 
studies reported that QoL appears to be unaffected by donor type. (Evans, Hart, & 
Manninen, 1984),( Tayebi, A., et al.,2010).At different forms of transplantation, cadaveric 
or living transplant may cause  different feelings of fear and guilt with no effect on  quality 
of life, as a point of fact, feelings of guilt appear to be prominent in living donor type 
transplantation( Griva K. et al.,2002) . 
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Chapter 6 : Conclusion 
 
This study was conducted to evaluate QoL among renal transplant patients who visit MOH 
facilities in Bethlehem and North Hebron by using disease-specific Kidney Transplant 
Questionnaire in Arabic version and to identify the effect of socio-demographic variables 
on the QoL for these patients. 
Quality of life for kidney transplant patients in our sample was moderate (4.02).While the 
lowest and highest scores of KTQ dimensions were related to fear/uncertainty and 
appearance; respectively. This low scores of fear/uncertainty dimension is related to the 
donor type in our sample which was about (66.1%) biologically blood related (father, 
mother, brother) the recipients had different feelings of fear, stress and guilt about their 
relative donors. 
The marital status was the only socio-demographic variable which has a negative statistical 
significant effect on quality of life for married recipients and a positive for single, while 
other socio-demographic variables like gender, age, education level, job status( 
employment), income level, donor type, immunosuppressive therapy, time after transplant, 
duration of dialysis before renal transplantation ,causes of ESRD, Physical problems, if 
undergone more than one renal transplant and smoking have no significant effect on QoL. 
The majority of kidney transplant recipients, were married male, without work, with low 
even no income and had a lot of responsibilities towered their health and families. So they 
were dependent on social security. 
About half (47.7%) of patients of our sample was attributed ESRD to (other reasons) 
which is higher than the range worldwide (5–20%) this result about cause of ESRD points 
to the necessity of improved pre-ESRD work-up. While the most common physical 
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problems that faces the patients after renal transplantation was aching and tired legs 
(68.8%) followed by very little strength (61.5%), aching bones (60.6%), muscle pain 
(52.3%). 
This results of our study points to the need for support from the whole society, 
government, family, and medical staff, and the need to design plans for solving recipients 
problems and increasing their quality of life. 
Our study is the first study assessing QoL among kidney transplant patients in Palestine 
conducting by face-to-face interviews to obtain more complete and high reliable data 
collection. This data will serve as baseline measurement for future QoL evaluation. 
 
Limitations 
 The sample size of the present study was relatively small, there may be a need for 
larger sample size to verify our findings. 
 Renal functions of the recipients were not investigated in the present study. 
 The lack of general national statistics and surveys in public health sector. 
 
Recommendations 
 Provide medical treatment for  physical problems that face the patients.  
 Provide financial support for kidney transplant patients.  
 Increase the focus on emotional, cognitive and social aspects of health. 
 Give the psychological consultation before and after the transplant surgery and 
maintaining it up at regular intervals as needed by experts. 
 The need to have other medical specialists available for kidney transplant patients. 
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 2 xidneppA
 استمارة زراعة الكمى
حوؿ حالتؾ المنصرميف. وسيتـ سؤالؾ  الأسبوعيفىذه الاستمارة صممت لتقييـ شعورؾ العاـ خلاؿ 
 النفسية، والأعراض الجسدية و المشاكؿ التي تعرضت ليا. 
المرضى المصابوف بأمراض الكمى كثيرا ما يشكوف مف أعراض ومشاكؿ جسدية. ما ىي  -1
والمشاكؿ الجسدية التي تعرضت ليا في الأسبوعيف المنصرميف. المقصود ىي أعراض أو  الأعراض
ليومية واف تكوف قد تعرضت ليا أكثر مف مرة. الرجاء ذكر مشاكؿ جسدية ميمة أو مؤثرة في حياتؾ ا
 جميع المشاكؿ التي واجيتيا وتخطر ببالؾ. 
(ضع دائرة حوؿ الرقـ المناسب عمى ورقة الإجابة الخاصة بػ " المشاكؿ أو الأعراض الجسدية " . اذا 
ىؿ تستطيع  لمتوفر)كاف ىناؾ عرض أو مشكمة غير مذكور في القائمة أضفو إلى القائمة في الفراغ ا
المنصرميف (سجؿ النقاط  الأسبوعيفمشاكؿ جسدية تعرضت ليا خلاؿ  تذكر أي أعراض أو
 )الإضافية
لائحة مف الأعراض والمشاكؿ الجسدية التي قد يتعرض ليا المرضى  بقراءة الآفسوؼ أقوـ  -2
مف الوقت حتى  الكمى في حياتيـ اليومية. سوؼ أتوقؼ بعد كؿ بند فترة كافية بأمراضالمصابيف 
المنصرميف.  إذا لـ تكف قد تعرضت  الأسبوعيفكنت قد تعرضت لو خلاؿ  إفتستطيع أف تحدثني 
 .لالممشكمة أو الأعراض فقط أجب بػ 
(قـ بقراءة البنود دوف ذكر تمؾ التي سبؽ أف وضحيا المريض. توقؼ بعد كؿ بند حتى تعطي 
 الأسبوعيفلمعرض أو المشكمة الجسدية خلاؿ  المريض فرصو ليذكر إذا ما كاف ىو/ىي قد تعرض/ت
 .)الإجابةالمنصرميف. ضع دائرة حوؿ الرقـ المناسب في ورقة 
 .فقداف الوزف وضمور العضلات -1
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 .نقص في القدرات الذىنية -2
 .جفاؼ أو حكة في الجمد -3
 .عدوى / التيابات -4
 .ىبوط في ضغط الدـ -5
 .الحرج مف التغييرات الخارجية في المظير -6
 .الأرجؿ آلاـ وتعب في -7
 .السعاؿ أثناء النيار أو الميؿ -8
  .وىف وضعؼ القوى -9
 .أعراض جانبية مف الأدوية -01
 .النسياف -11
 .التشوش أو الإلتباس -21
 .آلاـ في العظاـ -31
 .صعوبة في النـو -41
 .صعوبة التحكـ بالإخراج -51
 .الإسياؿأو  الإمساؾ -61
 .المراجعة / الاستفراغ -71
 .صداع -81
 .آلاـ المعدة أوالغثياف  -91
  .الرعشة -02
 .أثناء الميؿالاستيقاظ  -12
 07
 
 .فقداف الشيية -22
 .الدوخة أو الدوار أثناء القياـ بالنشاطات اليومية -32
 .الشعور بضيؽ التنفس أثناء القياـ بالنشاطات اليومية -42
 ضعؼ في القدرة الجنسية -52
 .صعوبة في الانتباه -62
 .صعوبة في التركيز -72
 .يحتاج إلى الراحة بشكؿ متكرر بسبب ضيؽ التنفس -82
 .زيادة في الشيية -92
 .رطة في الوزفزيادة مف -03
 .بثور في الوجو -13
 .انعداـ النـو المريح -23
 .آلاـ في العضلات -33
مف قائمة الأشياء التي ذكرَتيا ما ىو الأكثر أىمية في حياتؾ اليومية؟ سوؼ أقراء القائمة  – أ -3
 تذكر لي أي مف البنود ىو الأكثر أىمية؟ أفالقراءة أرجو  إنياءوعند 
  .ض كذلؾ تمؾ التي أضافيا في نياية القائمة)(إقراء جميع البنود التي ذكرىا المري
مف البنود المتبقية أي منيا ىو الأىـ لؾ في حياتؾ اليومية؟ سوؼ أقرأ لؾ جميع البنود وعند  -ب
 .القراءة أود أف تذكر لي أّي مف البنود ىو الأكثر أىمية إنياء
 .ما تبقى مف بنود في القائمة) إقراء(
  .الأىـ بالنسبة لؾ في حياتؾ اليوميةأي مف ىذه البنود ىو 
 .)الإجابةعمى ورقة  الإجابات(قـ بتدويف 
 17
 
  .أي مف البنود المتبقية ىو الأىـ لؾ في حياتؾ اليومية -جـ
 )الإجابةعمى ورقة  الإجابات(قـ بتدويف 
 أي مف البنود المتبقية ىو الأىـ لؾ في حياتؾ اليومية  -د
 )جابةالإعمى ورقة  الإجابات(قـ بتدويف 
 أي مف البنود المتبقية ىو الأىـ لؾ في حياتؾ اليومية  -ػ ه
 عمى ورقة الاجابة) الإجابات(قـ بتدويف 
 أي مف البنود المتبقية ىو الأىـ لؾ في حياتؾ اليومية  -و
 )الإجابةعمى ورقة  الإجابات(قـ بتدويف 
 أماـ المريض/ة عند طرح السؤاؿ) بةبالإجا(لكؿ مف الأسئمة التالية تأكد مف أف تكوف البطاقة الخاصة 
أرجو أف تصؼ مدى المشقة والانزعاج التي سببتيا( استعمؿ عدد الأعراض التي حددىا المريض) 
 أعراض خلاؿ الأسبوعيف المنصرميف.
) خلاؿ  -أ-3مف البند  الأعراضالرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استعمؿ  -1
 باختيار أحد الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء) الأسبوعيف المنصرميف، وذلؾ
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
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) خلاؿ  -ب-3مؿ الاعراض مف البند الرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استع -2
 الأسبوعيف المنصرميف، وذلؾ باختيار أحد الخيارات المدونة في البطاقة أمامؾ (البطاقة الخضراء)
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 نزعاجلـ أشعر بالإ )7
) خلاؿ  -جػ-3الرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استعمؿ الأعراض مف البند  -3
 الأسبوعيف المنصرميف، وذلؾ باختيار أحد الخيارات المدونة في البطاقة أمامؾ (البطاقة الخضراء)
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 طة مف الانزعاجدرجة متوس )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
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) خلاؿ  -د-3الرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استعمؿ الاعراض مف البند  -4
 الأسبوعيف المنصرميف، وذلؾ باختيار أحد الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء)
 الإنزعاجدرجة كبيرة جدًا مف  )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
) خلاؿ  -ىػ-3مف البند  الأعراضالرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استعمؿ  -5
 نة في البطاقة أمامؾ (البطاقة الخضراء)الأسبوعيف المنصرميف، وذلؾ باختيار أحد الخيارات المدو 
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
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خلاؿ )  -و-3الرجاء تحديد مدى المشقة والانزعاج الذي سببيا (استعمؿ الاعراض مف البند  -6
 الأسبوعيف المنصرميف، وذلؾ باختيار أحد الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء)
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
 الاسبوعيف المنصرميف بسبب الشيية المفرطة؟  ما مدى الإنزعاج خلاؿ -7
الرجاء تحديد مدى المشقة والانزعاج الذي سببتيا الشيية المفرطة خلاؿ الأسبوعيف المنصرميف، وذلؾ 
 باختيار أحد الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء)
 درجة كبيرة جدًا مف الإنزعاج )1
 درجة كبيرة مف الإنزعاج )2
 مف الانزعاجكثير  )3
 درجة متوسطة مف الانزعاج )4
 بعض الإنزعاج )5
 قميؿ مف الإنزعاج )6
 لـ أشعر بالإنزعاج )7
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خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحديد مقدار الوقت  بالضعؼ تشعر كـ مف الوقت كنت -8
خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات المدونة في بالضعؼ الذي شعرت بو 
 اقة أمامؾ (البطاقة الزرقاء)البط
 .في جميع الأوقات )1
 .في أغمب الأوقات )2
 .في معظـ الأوقات )3
 .في بعض الأوقات )4
 .في قميؿ مف الأوقات )5
  .نادرا )6
 .لـ أشعر بيذه الأعراض )7
كـ مف الوقت كنت تشعر قمة الصبر خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحديد مقدار الوقت  -9
الأسبوعيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات المدونة الذي شعرت بو بقمة الصبر خلاؿ 
 في البطاقة أمامؾ (البطاقة الزرقاء)
 .في جميع الأوقات )1
 .في أغمب الأوقات )2
 .في معظـ الأوقات )3
 .في بعض الأوقات )4
 .في قميؿ مف الأوقات )5
  .نادرا )6
 .لـ أشعر بيذه الأعراض )7
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لأسبوعيف المنصرميف؟ الرجاء تحديد مقدار خلاؿ ا والحزف كـ مف الوقت كنت تشعر بالاكتئاب -11
الوقت الذي شعرت بو بالاكتئاب خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات 
 المدونة في البطاقة أمامؾ (البطاقة الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
كـ مف الوقت كنت تشعر بالعناد خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحديد مقدار الوقت الذي  -11
شعرت بو بالعناد خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات المدونة في البطاقة 
 أمامؾ (البطاقة الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 ي معظـ الأوقاتف )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
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خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحديد مقدار  والكسؿ  كـ مف الوقت كنت تشعر بالخموؿ -21
الوقت الذي شعرت بو بالخموؿ خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات 
 بطاقة أمامؾ (البطاقة الزرقاء)المدونة في ال
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحديد مقدار الوقت واليـ كـ مف الوقت كنت تشعر بالقمؽ  -31
عيف المنصرميف، وذلؾ باختيار واحدة مف الخيارات المدونة في الذي شعرت بو بالقمؽ خلاؿ الأسبو 
 البطاقة أمامؾ (البطاقة الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
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صرميف بسبب ضعؼ القوى؟ ما مدى الصعوبة أو المشقة التي واجيتيا خلاؿ الأسبوعيف المن -41
الرجاء تحديد مدى الصعوبة والمشقة التي واجيتيا خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار واحدة 
 .مف الخيارات المدونة في البطاقة أمامؾ (البطاقة البيضاء)
  .والمشقة درجة كبيرة جدًا مف الصعوبة )1
 .درجة كبيرة مف الصعوبة والمشقة )2
 .مشقةكثير مف الصعوبة وال )3
 .درجة متوسطة الصعوبة والمشقة )4
 .بعض الصعوبة والمشقة )5
 .قميؿ مف الصعوبة والمشقة )6
 .لا صعوبة أومشقة )7
كـ شعرت بالخوؼ أو قمؽ حياؿ رفض الجسـ لمعضو المزروع؟ الرجاء تحديد شعورؾ بالخوؼ  -51
البطاقة  أو القمؽ حياؿ رفض الجسـ لمعضو المزروع، وذلؾ باختيار واحدة مف الخيارات المدونة في
  .أمامؾ (البطاقة الزرقاء)
 .في جميع الأوقات )1
 .في أغمب الأوقات )2
 .في معظـ الأوقات )3
 .في بعض الأوقات )4
 .في قميؿ مف الأوقات )5
  .نادرا )6
 .لـ أشعر بيذه الأعراض )7
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كـ شعرت بالقمؽ إزاء مستقبمؾ خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحيد شعورؾ بالقمؽ إزاء  -61
 ر واحدة مف الخيارات المدونة في البطاقة أمامؾ (البطاقة الزرقاء)مستقبمؾ، وذلؾ باختيا
 .في جميع الأوقات )1
 .في أغمب الأوقات )2
 .في معظـ الأوقات )3
 .في بعض الأوقات )4
 .في قميؿ مف الأوقات )5
  .نادرا )6
 .لـ أشعر بيذه الأعراض )7
لؾ خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحيد شعورؾ بالقمؽ، وذوالخوؼ  كـ شعرت بالقمؽ -71
 .باختيار واحدة مف الخيارات المدونة في البطاقة أمامؾ (البطاقة الزرقاء)
 .في جميع الأوقات )1
 .في أغمب الأوقات )2
 .في معظـ الأوقات )3
 .في بعض الأوقات )4
 .في قميؿ مف الأوقات )5
  .نادرا )6
 .لـ أشعر بيذه الأعراض )7
 
 08
 
الرجاء تحديد مدى  ما مدى الإنزعاج خلاؿ الاسبوعيف المنصرميف بسبب زيادة في نمو الشعر؟ -81
المشقة والانزعاج الذي سبتيا الزيادة في نمو الشعر خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار أحد 
 الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء)
 الإنزعاج درجة كبيرة جدًا مف )1
 درجة كبيرة مف الإنزعاج )2
 كثير مف الانزعاج )3
 درجة متوسطة مف الانزعاج )4
 عض الإنزعاجب )5
 قميؿ مف الإنزعاج )6
 بالإنزعاج لـ أشعر )7
 ما مدى الإنزعاج خلاؿ الاسبوعيف المنصرميف بسبب زيادة في الوزف؟ 91- 
الرجاء تحديد مدى المشقة والانزعاج الذي سبتيا الزيادة في الوزف خلاؿ الأسبوعيف المنصرميف، وذلؾ 
 لبطاقة الخضراء)باختيار أحد الخيارات المدونة في البطاقة أمامؾ ( ا
 درجة كبيرة جدًا مف الإنزعاج
 درجة كبيرة مف الإنزعاج
 كثير مف الانزعاج
 درجة متوسطة مف الانزعاج
 بعض الإنزعاج
 قميؿ مف الإنزعاج
 لـ أشعر بالإنزعاج
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 ما مدى الإنزعاج خلاؿ الاسبوعيف المنصرميف بسبب البثور في الوجو؟ 02- 
بتيا البثور في الوجو خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار الرجاء تحديد مدى الانزعاج الذي س
 أحد الخيارات المدونة في البطاقة أمامؾ ( البطاقة الخضراء)
 درجة كبيرة جدًا مف الإنزعاج
 درجة كبيرة مف الإنزعاج
 كثير مف الانزعاج
 درجة متوسطة مف الانزعاج
 بعض الإنزعاج
 قميؿ مف الإنزعاج
 لـ أشعر بالإنزعاج
كـ شعرت بالحرص عمى كميتؾ المزروعة خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحيد شعورؾ 12- 
بالحرص عمى كميتؾ المزروعة، وذلؾ باختيار واحدة مف الخيارات المدونة في البطاقة أمامؾ (البطاقة 
 الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 ف الأوقاتفي قميؿ م )5
 نادرا  )6
 لـ أشعر بذلؾ )7
 28
سمس في المعاممة خلاؿ الأسبوعيف المنصرميف؟  وغير أنؾ عصبي شعرتكـ مف الوقت  22- 
الرجاء تحيد شعورؾ أنؾ عصبي وغير سمس في المعاممة، وذلؾ باختيار واحدة مف الخيارات المدونة 
 في البطاقة أمامؾ (البطاقة الزرقاء)
 في جميع الأوقات )1
 لأوقاتفي أغمب ا )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
ما مدى الصعوبة أو المشقة التي واجيتيا خلاؿ الأسبوعيف المنصرميف بسبب الاجياد والتعب؟ 32-
واحدة  الرجاء تحديد مدى الصعوبة والمشقة التي واجيتيا خلاؿ الأسبوعيف المنصرميف، وذلؾ باختيار
 مف الخيارات المدونة في البطاقة أمامؾ (البطاقة البيضاء)
 درجة كبيرة جدًا مف الصعوبة والمشقة  )1
 درجة كبيرة مف الصعوبة والمشقة )2
 كثير مف الصعوبة والمشقة )3
 درجة متوسطة الصعوبة والمشقة )4
 بعض الصعوبة والمشقة )5
 قميؿ مف الصعوبة والمشقة )6
 لا صعوبة أومشقة )7
 38
 
شعرت بالاحباط العاـ في المعاممة خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحيد كـ مف الوقت 42- 
 شعورؾ بالاحباط العاـ، وذلؾ باختيار واحدة مف الخيارات المدونة في البطاقة أمامؾ (البطاقة الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 ـ أشعر بيذه الأعراضل )7
كـ مف الوقت شعرت بانخفاض في مستوى الطاقة خلاؿ الأسبوعيف المنصرميف؟ الرجاء تحيد 52- 
شعورؾ بانخفاض في مستوى الطاقة، وذلؾ باختيار واحدة مف الخيارات المدونة في البطاقة أمامؾ 
 (البطاقة الزرقاء)
 في جميع الأوقات )1
 في أغمب الأوقات )2
 في معظـ الأوقات )3
 في بعض الأوقات )4
 في قميؿ مف الأوقات )5
 نادرا  )6
 لـ أشعر بيذه الأعراض )7
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وزارة الصحة الفمسطينية في محافظة بيت لحم في عيادات نوعية الحياة لمرضى زراعة الكمى 
 وشمال الخميل.
 إعداد: خمود حسن طافش ذويب
 قحسين الحلا  : د.إشراف
 :الممخص
مرض لة يائي ّلنتيجة مرضى المرحمة الن ّ ا ًقوي ّ ا ًر ) مؤش  efiL fo ytilauQالحياة ( جودة ُتعَتبر: ةفي  م  الخ  
مى في ة الحياة لممرضى الذيف يعانوف مف مرض الك ِمى ىو تحسيف نوعي ّع الك ِر ْمى. الغرض مف ز َالك ِ
راسة كاف اليدؼ مف ىذه الد ّبناًء عميو، مرضى. العلاج الأمثؿ ليؤلاء التو الّنيائّية، حيث ُيَعدُّ مرحم
 مى في بيت لحـ وشماؿ الخميؿ في فمسطيف.ع الك ِر ْمرضى ز َ لدىالحياةقياس مؤش ر جودة
وزارة  ت ّـَ إحالتيـ إلىمى ع الك ِر ْز َلض يمر  901ة مستعرضة عمى في ّص ْدراسة و َ ت ّـَ إجراء: ريقةالط  
 في الفترة ما بيفة في بيت لحـ وشماؿ الخميؿ في فمسطيف ي ّلة الأو ّحي ّعاية الص ّعيادات الر ّو ةح ّالص ّ
مؤش ر تقييـ ل) 52-QTKمى (ع الك ِر ْ، وذلؾ باستخداـ استبياف ز َ7102 نيسافإلى  6102 كانوف الأّوؿ
ة تحديد موثوقي ّ ة الحياة. ت ّـَ ة عمى نوعي ّيموغرافي ّة والد ّرات الإجتماعي ّتحديد تأثير المتغي ّو الحياة جودة
 ت ّـَ  ، كما47.0) وكانت ahplA s'hcabnorC( بواسطة طريقة كرونباخ ألفا) 52-QTKاف (الاستبي
 .SSPS 91بواسطة البرنامج الإحصائي  ةتحميؿ البيانات والإحصاءات الوصفي ّ
). وكانت أعمى درجة 48.0±  20.4مى (ع الك ِر ْالحياة لمرضى ز َمؤش ر جودةط : كاف متوس تيجةالن  
عدـ حصمت فئة "في حيف  ،)32.1±  04.5( "ري َظ ْالم َفئة"ىي 52-QTKمف استبياف
نة عي ّالنت تكوَّ بالّنسبة لممعمومات الّديموغرافّية، فقد ).32.1±  63.3درجة ( أدنى"عمى اليقيف/الخوؼ
±  14ط عمرىـ (كاف متوس  ،الإناث% مف 2.02ًا وذكور  %8.97يـ مى منع الك ِر ْز َ مريض 901مف 
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ؿ خ ْذوي د َ %2.35بدوف عمؿ، و  %9.54، و %7.18جوف بنسبة و  ) سنة. وكاف معظميـ متز 42
 ةنوع الجي.أّما بالّنسبة لأخرى إلى أسباب ٍ تب َس ِن ُ %7.74وبالنسبة الى سبب الفشؿ الكموي منخفض، 
ىي ة شيوعا ًالمشاكؿ الجسدي ّ أكثر ـ. وكانتذات صمة بالد ّمصدر  % مف1.66 كاف،فالمانحة لمكمية
 ة الحياةة عمى نوعي ّوجي ّتأثير معنوي لمحالة الز ّ تّـَ ملاحظة وجود). %8.86( ْيفوَتَعْب القدم َ الأَل ْـ
 ،)430.0 = p( أولئؾ المتزو جوفأعمى مف  لممرضى غير المتزو جيفة الحياة نوعي ّمؤش ر كاف  حيث
 ة الحياة.نوعي ّو ة الأخرى يموغرافي ّة الد ّرات الاجتماعي ّ) بيف المتغي ّ50.0> p( كبير ٌ فرؽ ٌ َيُكْف ىناؾم ْول َ
 ىذه الّدراسة. وتشير نتائج متوس طة ىذه الّدراسةمى في ع الك ِر ْالحياة لمرضى ز َ جودة ت: كانالاستنتاج
والّطاقـ الط ّبي خاّصًة، الأسرة  عاّمًة، ومف والحكومة َكُكؿـ مف المجتمع ع ْإلى الحاجة إلى الدَّ 
زيادة لمى ع الك ِر ْز َالتي يواجييا مرضى شاكؿ مبعض ال ؿح َط ل ِط َخ ُ وضعإلى  بالإضافة إلى الحاجة
 . حياتيـ جودة
مى ، فمسطيفع الك ِر ْمى، استبياف ز َع الك ِر ْ: جودة الحياة، ز َالةالکممات الد  
